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Abstract 
 
Anxiety disorders are one of the most prevalent mental disorders in the 
world. While “normal” anxiety serves as an important protective mechanism, 
“pathological” anxiety characteristic of an anxiety disorder is both maladaptive and 
disruptive. The majority of studies have focused on the neurotransmitter systems 
associated with the actions of known anxiety drugs.  This focus may likely limit the 
exploration of mechanisms underlying anxiety disorders.  This project aims to 
examine changes in gene expression that may underlie higher or lower levels of 
inherent anxiety. 
Using a well-established behavior test for anxiety, the elevated plus maze, 
we identified male Wistar rats exhibiting inherently high- or low-anxiety levels. 
Brain regions known to mediate anxiety, the amygdala, hippocampus and nucleus 
accumbens, were dissected and total mRNA isolated. The mRNA was converted to 
cDNA via reverse transcription-polymerase chain reaction (RT-PCR). Then, the 
cDNA was used in suppression subtractive hybridization, a technique used to 
compare two complete populations of cDNAs and identify cDNAs that are 
upregulated in one population in relation to the other. In this project suppression 
subtractive hybridization was used to compare high- and low-anxiety cDNA 
populations. The upregulated cDNAs were amplified in a PCR reaction that enables 
rare transcripts to be identified.  The PCR products from the suppression subtractive 
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hybridization were cloned and used to create two cDNA libraries for high- and low-
anxiety related genes.  These clones were sequenced to show over 1000 genes 
upregulated in high- and low-anxiety. The gene list was then subjected to 
bioinformatic analysis to identify one candidate to be studied in further detail. 
The prion protein was identified as a potential candidate. Examination of the 
literature sparked an interest in studying other prion-like proteins, more specifically 
the cytoplasmic polyadenylation element binding protein (CPEB).  The CPEB 
protein is a potent regulator of mRNA translation in both mature oocytes and the 
adult brain.  While unphosphorylated the CPEB protein keeps specific mRNAs 
dormant in the cytoplasm. In its phosphorylated form CPEB catalyzes 
polyadenylation of the mRNA, leading to protein synthesis. 
PCR was used to show the presence of CPEB mRNA transcripts in the rat 
hippocampus.  CPEB protein expression was examined in the brain samples isolated 
from control, high- and low-anxiety rats.  It was found that CPEB was significantly 
upregulated in high- and low-anxiety rats compared to control.  The protein 
expression of an upstream kinase, Aurora A kinase, and a downstream target, 
Calcium/Calmodulin Dependent Kinase II (CaMKII), was also investigated.  The 
results from Aurora A kinase were inconclusive.  CaMKII, on the other hand, was 
significantly upregulated in high-anxiety over both control and low-anxiety.  These 
results suggest that CPEB may catalyze increased translation of mRNAs in high-
anxiety while acting as a repressor of those same mRNAs in low-anxiety. 
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 Recent studies have suggested that CPEB protein plays an important role in 
synaptic plasticity.  The regulation of synaptic plasticity, and its impact on learning 
and memory, is believed to be a key mechanism behind the maintenance of anxiety 
disorders.  Therefore the results of this study suggest a new molecular mechanism in 
the development of anxiety disorders.     
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1 Introduction 
 
1.1 Normal Anxiety 
 
Anxiety is a biologically important mechanism conserved across many 
species.  Normal anxiety serves as an adaptive response to potentially threatening 
situations (Clement et al., 2002; Finn et al., 2003; Sandford et al., 2000). Anxiety 
allows an organism to protect itself against future danger by responding to 
threatening stimuli through characteristic responses of fight, flight or freezing (Finn 
et al., 2003; Gordon and Hen, 2004; Sandford et al., 2000).  In humans anxiety may 
also be expressed psychologically as worry (Antony and Swinson, 1996; Finn et al., 
2003).  These anxious reactions enable an organism to evaluate a threatening 
situation and react in an appropriate manner to reduce the risk of harm (Antony and 
Swinson, 1996). 
 
1.2 Pathological Anxiety   
 
Although anxiety is an important protective mechanism it can become 
maladaptive and disruptive (Clement et al., 2002; Finn et al., 2003; Sandford et al., 
2000).  Pathological anxiety, as manifested in anxiety disorders, is an anxious 
response that occurs out of proportion to the threat, becomes disruptive to daily life 
and causes suffering (Antony and Swinson, 1996; Clement et al., 2002; Finn et al., 
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2003; Sandford et al., 2000). Although many authors see pathological anxiety not as 
a separate and unique state from normal anxiety but as an extreme expression of it 
(Finn et al., 2003; Lesch, 2001; Sandford et al., 2000), anxiety disorders may be 
defined as a collection of psychological problems that include excessive anxiety, 
worry, fear and avoidance (Antony and Swinson, 1996).   Diagnostically, the 
difference between normal and pathological anxiety can be said to lie in the fact that 
the latter is disruptive and causes suffering for an individual. 
Anxiety disorders are divided into five major diagnoses according to the 
Diagnostic and Statistical Manual IV.  These five disorders are generalized anxiety 
disorder, obsessive compulsive disorder, phobias, panic disorder and post traumatic 
stress disorder (PTSD). While anxiety disorders may be classified into five 
categories they are not isolated from each other, and many of their behavioral and 
physiological symptoms overlap (Finn et al., 2003; Gross and Hen, 2004).  Also, 
many of the disorders respond to the same treatment, highlighting underlying 
commonalities between disorders. 
  Anxiety disorders affect a large proportion of the population worldwide.  
An estimated 30 million people in the United States alone will experience an 
anxiety disorder at some point in their lives (Finn et al., 2003; Lepine, 2002).  
Associated with anxiety disorders are large personal and socio-economic costs 
ranging from medical treatments to reduced workplace productivity to suicide 
(Antony and Swinson, 1996; Lepine, 2002).  As a result of these (and other) factors 
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there is a great deal of interest in discovering the underlying mechanisms of anxiety 
disorders in order to improve diagnosis and treatment of these complex disorders. 
 
1.3 Animal Behavior Models 
 
While anxiety is believed to be a uniquely human trait, anxiety-like 
behaviors have been observed across many other species.  As a result, animal 
models can be used to obtain information about molecular mechanisms involved in 
anxiety that would be impossible in humans.  Animal models allow investigators to 
test hypotheses under controlled conditions and using methods that would be 
difficult to manage in humans (Hitzemann, 2000; Kalueff and Tuohimaa, 2004).  
 Unfortunately many difficulties arise when modeling human psychiatric 
disorders, such as anxiety disorders, in another species. The major difficulty in 
modeling anxiety disorders in animals is that they are not capable of verbal 
communication which is a critical component of diagnosing psychiatric disorders.  It 
is difficult to identify analogous behaviors (Kalueff and Tuohimaa, 2004). It is also 
difficult to distinguish between fear and anxiety.  The behavioral and physiological 
responses in fear and anxiety are highly similar. The distinction between fear and 
anxiety lies in the concept that the former is a response to an actual threat while the 
latter is a response to a potential threat (Belzung and Griebel, 2001; Gordon and 
Hen, 2004; Gray and McNaughton, 2000).  This definition is ambiguous in animals 
so anxiety in animals can only be implied at best.  Lastly, there are structural and 
 4
functional differences between the nervous systems of animals and that of humans 
(Kalueff and Tuohimaa, 2004).   Therefore, the accuracy of the data obtained using 
animal models is dependent on the validity of the model (Kalueff and Tuohimaa, 
2004).  
 
1.3.1 Conditioned Tests 
 
In the field of anxiety research there are two main categories of animal 
models: those that involve conditioned responses and those that involve 
unconditioned responses (Rodgers and Dalvi, 1997).  Conditioned tests combine 
elements of learning and memory with aversive stimuli and require pre-test training 
paradigms. They measure a conditioned response, in other words, a specific 
response that is learned through association with an aversive stimulus (Hitzemann, 
2000). Examples of conditioned tests are fear-potentiated startle and Geller-Seifter 
conflict (Hitzemann, 2000; Rodgers and Dalvi, 1997).  Conditioned tests require 
extensive pre-test training and often use food/water deprivation or electric shock as 
an aversive stimulus (Rodgers and Dalvi, 1997).  The required pre-test training 
associated with conditioned tests makes them more amenable to experimental 
manipulation than unconditioned tests (Flint, 2003). 
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1.3.2 Unconditioned tests 
 
Unconditioned tests on the other hand do not require time consuming pre-
test training as they measure un-learned, inherent anxiety.  Unconditioned tests 
include the open field, light-dark transition and elevated plus maze tests 
(Hitzemann, 2000).  Unconditioned tests are believed to be more sensitive to stress 
compared to conditioned tests as the latter tend to use strong and often painful 
stressors such as foot shock.  It is argued that these stressors may suppress activity 
and cause complex changes in animal behaviors, making interpretation of results 
difficult (Kalueff and Tuohimaa, 2004).   
 
1.3.3 The Elevated Plus Maze test 
 
The elevated plus maze (EPM) is a simple and highly validated behavioral 
test for anxiety in rodents.  The history of the EPM goes back to the 1950’s when 
Montgomery observed that rats showed high levels of exploration (and therefore 
preference) for elevated enclosed alleys over elevated open alleys (Pellow et al., 
1985; Rodgers and Dalvi, 1997).  He inferred that since both alleys were novel and 
would therefore produce the same drive to explore, the rat’s avoidance of the open 
arms was the result of a fear response (Rodgers and Dalvi, 1997). 
 Based on Montgomery’s findings Handley and Mithani developed the EPM 
(Pellow et al., 1985; Rodgers and Dalvi, 1997).  The maze consisted of two open 
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arms set across from each other and two closed arms set at 90° to the open arms 
(Figure 2.1).  The apparatus’ ability to measure anxiety-like behavior was 
established through the ability of anxiolytics and anxiogenics to affect the behavior 
within the apparatus (Pellow et al, 1985). 
 Since its first description, the EPM test has been validated 
pharmacologically, physiologically and behaviorally and has become one of the 
most widely used behavioral tests for anxiety-like behavior (Gordon and Hen, 2004; 
Hogg, 1996; Pellow et al., 1985; Rodgers and Dalvi, 1997). Montgomery’s view 
that aversion to the open arms reflected fear or anxiety has been validated 
behaviorally as rats display more anxiety-related behaviors, including freezing and 
defecation, in the open arms compared to the closed arms. Physiologically, rats 
confined to the open arms show higher levels of plasma corticosterone than those 
confined to the closed arms (Cruz et al, 1994; Hogg, 1996; Pellow et al, 1985). As 
corticosterone is a stress hormone, its increased release strongly suggests that the 
open arms create an increased stress response in rats (Pellow et al., 1985).  Finally, 
agents that increase anxiety levels (anxiogenics) decrease the amount of time spent 
in the open arms while agents that decrease anxiety (anxiolytics) predictably 
increase the amount of time spent in the open arms (Cruz et al, 1994; Hogg, 1996; 
Pellow et al, 1985; Rogers and Dalvi, 1997). 
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1.3.4 Elevated Plus Maze measurements 
  
As the EPM measures the conflict between the drive exploration and 
aversion to the open arms, the major behavioral measure is the exploration of the 
open arms.  Exploration of the open arms can be measured by two methods.  One is 
the number of entries into the open arms expressed as a total number or as a 
percentage of open versus total arm entries.  A second measure is the amount of 
time spent on the open arms (Cruz et al., 1994; Rogers and Dalvi, 1997).  Behaviors 
other than exploration, such as freezing, grooming or risk assessment, have been 
examined as other possible indices of anxiety (Cruz et al., 1994; Rogers and Dalvi, 
1997).  Unfortunately, these ethological measures are time-consuming and tend to 
require video capture systems and thus are not always practical (Cruz et al., 1994). 
 As with all behavioral tests, the EPM is sensitive to many outside factors. 
Therefore the procedure needs to be standardized and great attention needs to be 
spent on maintaining these standards.  Housing conditions, lighting, test duration 
and prior handling have all been shown to affect the test results.  These outside 
factors are believed to be the root cause of variation in results seen between 
laboratories (Rogers and Dalvi, 1997). 
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1.4 Brain Regions involved in Anxiety 
 
The complexity of anxiety disorders suggests numerous areas of the brain 
are involved. The brain regions associated with anxiety have been identified through 
numerous lesion and microinjection studies in animals and human neuroimaging 
studies (Gordon and Hen, 2004).  A few of these regions will be briefly discussed 
here.   
The brain regions involved in anxiety are said to be organized into a 
hierarchy of responses.  The physiological responses are mediated by so called 
“lower areas” which include the locus coeruleus (LC), the periaqueductal grey 
matter (PAG) and the hypothalamus (Sandford et al., 2000).  The intermediate level 
(our area of interest) mediates the “practiced response” to anxiogenic stimuli and 
includes the amygdala and septo-hippocampal regions (Sandford et al., 2000). The 
final level of the hierarchy involves the higher cortical regions and directs complex, 
cognitive processing (Sandford et al., 2000).  Each of these levels has the ability to 
feedback into, and directs the response of, the level(s) below it (Sandford et al., 
2000). 
The LC is believed to be an important modulator of anxiety.  Activation of 
the LC, either by electrical stimulation or by drugs, elicits an anxiety response.  
Lesions that inactivate the LC reduce anxiety (Sandford et al., 2000). The LC 
contains the major norepinephrine (NE) producing neurons in the brain (Ressler and 
Nemeroff, 2000). It projects to the cerebellum, medulla and spinal cord along with 
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cortical, sub-cortical and limbic structures (Ressler and Nemeroff, 2000). It receives 
input from numerous brain stem nuclei including the hypothalamus, PAG and the 
amygdala (Ressler and Nemeroff, 2000).  The LC and its associated NE release are 
believed to control arousal, vigilance, activation of the stress response and 
modulation of memory (Ressler and Nemeroff, 2000).  Both novelty and stress have 
been shown to increases LC firing which results in increased vigilance and arousal 
(Ressler and Nemeroff, 2000).   
The PAG is believed to control the responses associated with fight and flight 
as stimulation of this area induces responses associated with fight and flight, such as 
changes in heart rate and decreased sensitivity to pain (Sandford et al., 2000).  The 
PAG receives inputs from the limbic system and various sensory structures 
(Sandford et al., 2000).  It has been hypothesized that the PAG is responsible for 
selecting, organizing, and executing the appropriate behavioral responses in reaction 
to information it obtains from the amygdala (Graeff et al., 1993). This direct control 
over the behavioral response has resulted in the hypothesis that the PAG is 
responsible for panic disorder (Graeff et al., 1993).    
 The hypothalamus is an important coordinator of the neuroendocrine 
response through activation of the hypothalamic-pituitary-adrenal axis.  The 
neuroendocrine response provides the metabolic and cardiovascular support for 
behavioral response (Chaouloff et al., 1999).  Signaling from the amygdala to the 
hypothalamus has been shown to mediate the neuroendocrine response to stressful 
and fearful stimuli, including plasma corticosterone release (Davis, 1992).   
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1.4.1 The Amygdala 
 
The amygdala has long been thought to be the center of a defense system 
involved in both the expression and acquisition of fear and anxiety (Lang et al., 
2000).  Expression of anxiety has been shown to require the transmission of 
information to and from the amygdala.  The amygdala receives information from the 
thalamus and the cortex, and that information is processed within the various 
amygdaloid nuclei.  The processed information is then sent out to targets in the 
hippocampus, brain stem, hypothalamus and other regions that direct behavioral, 
autonomic and stress hormone responses (Gordon and Hen, 2004). 
Not all of the 13 amygdaloid nuclei and numerous sub-nuclei are involved in 
anxiety. In fact only the central nucleus and basolateral complex (consisting of the 
lateral, basal and accessory basal nuclei) are believed to be essential.  These nuclei 
function as an interface between sensory input and motor output important for both 
the behavioral response to and the learning involved in anxiety (Rosen, 2004). The 
central nucleus of the amygdala receives input from the prefrontal cortex and, in 
turn, projects to numerous nuclei in the midbrain and brain stem.  These projections 
make significant contributions to the behavioral, autonomic and endocrine responses 
to danger (Rosen, 2004). 
The basolateral nucleus receives the majority of the sensory information 
from the thalamus and the cortex.  The basolateral complex also receives 
innervation from the hippocampus and the prefrontal cortex.  The role of the 
basolateral complex in anxiety is believed to be in the “emotional” evaluation of 
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sensory information.  This evaluation then influences other regions of the amygdala 
and brain to ensure an integrated response.  Efferents from the basolateral complex 
are believed to orchestrate active avoidance behaviors most likely through the 
nucleus accumbens, striatum and thalamus (Rosen, 2004).   
 
1.4.2 The Hippocampus   
 
A host of information has been building to suggest a major role of the 
hippocampus in fear and anxiety (McHugh et al., 2004).  The ventral region of the 
hippocampus is closely associated with the amygdala.  It has connections to and 
from the basal and lateral nuclei of the amygdala (McHugh et al., 2004).  Lesions of 
the ventral hippocampus have been shown to produce anxiolytic effects in various 
behavioral tests for anxiety.  Hippocampal lesions also decrease plasma 
corticosterone levels in animals exposed to stressful situations. As corticosterone 
levels reflect stress levels these results suggest the hippocampus has an important 
role in mediating the stress response. Lesions to the septo-hippocampal region, 
therefore, appear to produce the same effect as classical anxiolytics, like the 
benzodiazepines (Gray and McNaughton, 2000).   
In their text, “The neuropsychology of anxiety: an enquiry into the functions 
of the septo-hippocampal system”, Gray and McNaughton (2000) have put forward 
a septo-hippocampal-centric theory of anxiety.  They believe the hippocampus, not 
the popular amygdala, plays a central role in anxiety.  In their view, the 
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hippocampus can add positive or negative values to memories.  A hyperactive or 
hypersensitive hippocampus may be biased towards negative associations.  Thus, it 
would increase the negative value of experiences or preferentially store highly 
threatening associations (Gray and McNaughton, 2000).  This would prime one of 
the major centers of the brain to perceive incoming information as more threatening, 
triggering a reaction that is inappropriate to the level of threat, a hallmark of anxiety 
disorders.  
 
1.4.3 The Nucleus Accumbens 
 
The nucleus accumbens is divided into two regions, the central core and the 
peripheral shell, although the division is poorly characterized in humans and 
primates (Sturm et al., 2003).  The central core is associated with extrapyramidal 
motor functions, while the peripheral shell is associated with the limbic system.  
The shell is both biochemically and histologically similar to the central nucleus of 
the amygdala (Sturm et al., 2003).  In humans, the nucleus accumbens receives 
input from the basolateral, medial and central nuclei of the amygdala.  It projects to 
the pallidum, striatum, mediodorsal thalamus, prefrontal cortex and mesolimbic 
dopaminergic areas.  Thus, the nucleus accumbens occupies a central position 
between many of the brain regions involved in the development of anxiety disorders 
(Sturm et al., 2003). 
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1.5 Molecular Mechanisms of Anxiety  
 
Several environmental risk factors have been identified for anxiety disorders, 
such as severe abuse or overprotective parents (Antony and Swinson, 1996). Yet 
these risk factors are not sufficient in themselves, as not everyone who experiences 
known risk factors will develop an anxiety disorder.  For example, a traumatic 
event, such as participation in war, can cause PTSD, but not all individuals who 
experience a traumatic event will develop PTSD (Antony and Swinson, 1996; Gross 
and Hen, 2004).  This variance has been attributed to genetic influence. A genetic 
predisposition plus environmental factors combine to result in the expression of an 
anxiety disorder.  Family, twin and adoptee studies have calculated the genetic 
contribution of anxiety disorders to be 25-65% (Finn et al., 2003). 
 Early studies into the genetics of anxiety have investigated the role of 
various neurotransmitter systems including the adrenergic, dopaminergic, 
adenosinergic and cholecystokinin systems, although most studies have focused on 
γ-aminobutyric acid (GABA) and serotonin (5-HT) as they are the targets of known 
anxiolytics (Antony and Swinson, 1996; Finn et al., 2003; Gordon and Hen, 2004; 
Gross and Hen, 2004; Sandford et al., 2000).    
GABA is the primary inhibitory neurotransmitter in the brain (Kalueff and 
Nutt, 1996; Lydiard, 2003). GABA counteracts the activity of the excitatory 
neurotransmitter glutamate to maintain homeostasis.  It is hypothesized that in 
anxiety the GABA system is down-regulated, possibly resulting in a state of 
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excessive neuronal hyper-excitability (Lydiard, 2003).  The inhibitory function of 
GABA is mediated mainly thru the GABA-A receptor.  The GABA-A receptor is 
composed of five receptor subunits arranged around a central chloride channel and 
is highly expressed in many anxiety-related brain regions including the amygdala 
and hippocampus.  When GABA binds and activates the GABA-A receptor the 
chloride channel opens and chloride ions move into the neuron.  This influx inhibits 
neuronal activity by hyperpolarizing the cell, blocking neuronal depolarization 
(Kalueff and Nutt, 1996).   
Many anxiolytics impact GABA transmission by activating the GABA-A 
receptor.  The benzodiazepines exert their effects by making the GABA-A receptor 
more sensitive to the effects of GABA, enhancing the inhibitory action of GABA 
itself (Kalueff and Nutt, 1996). Other known, but obviously less popular, anxiolytics 
such as ethanol and barbiturates, affect the GABA-A receptor by directly opening 
its chloride channel (Kalueff and Nutt, 1996).  On the opposite end of the spectrum 
compounds that act as inverse agonists, which inhibit GABA-A activity, have been 
shown to produce severe anxiety in both human and animal studies (Kalueff and 
Nutt, 1996).   
Studies attempting to understand the finer details of the role of GABA in 
anxiety have examining the effects of inactivation of genes involved in GABA 
neurotransmission in animal models.  For example, inactivation of various subunits 
of the GABA-A receptor has been investigated along with various enzymes 
involved in the synthesis and metabolism of GABA.  Many of the GABA-A subunit 
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mutations had no measurable effect on the expression of anxiety although 
inactivation the γ2 subunit increased anxiety (Belzung and Griebel, 2001; Clement 
et al., 2002; Finn et al., 2003).  Inactivation of the GABA synthesis enzyme 
GAD65, resulted in increased anxiety, probably as the result of reduced amount of 
GABA available (Belzung and Griebel, 2001; Clement et al., 2002; Finn et al. 
2003).   
    The therapeutic benefits of some antidepressants, such as the selective 
serotonin reuptake inhibitors, have implicated 5-HT in anxiety.  The activity of 5-
HT in anxiety is complex as there are at least 14 subtypes of 5-HT receptors and 
some are inhibitory and others excitatory (Ressler and Nemeroff, 2000).  5-HT is 
believed to play a modulatory role in memory, behavior and mood (Ressler and 
Nemeroff, 2000).  There is extensive 5-HT innervation in brain regions associated 
with anxiety including the amygdala, hippocampus, PAG and hypothalamus 
(Chaouloff et al., 1999).  Activation of the 5-HT1A receptors in the hippocampus is 
believed to reduce anxiety by increasing the resilience of the hippocampus to 
aversive stimuli (Finn et al., 2003; Ressler and Nemeroff, 2000).  On the other hand, 
activation of the 5-HT2 receptors in the amygdala and hippocampus has been shown 
to increase anxiety (Finn et al., 2003).  While the therapeutic benefit of selective 
serotonin reuptake inhibitors suggest anxiety may be caused by a decrease in 5-HT 
transmission this is not conclusive as 5-HT activity can either increase or decrease 
anxiety on which receptor is being activated (Finn et al, 2003).    
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Like the GABAergic system, the 5-HT system has been studied using gene 
inactivation experiments.  Null mutation of the 5-HT1A receptor increased anxiety 
(Clement, et al., 2002; Finn et al., 2003, Gross and Hen, 2004), while a mutated 5-
HT1B mutation had no effect in two anxiety tests but decreased anxiety in a third test 
and mutation of the 5-HT5A receptor had no effect (Clement et al., 2002).  
The majority of genetic or molecular studies into anxiety have been directed 
by the actions of known anxiolytics. Unfortunately this reliance on anxiolytics may 
be limiting the field of study.  New molecular techniques are now available that 
allow the entire populations of expressed genes to be screened and identified.   
Recently, Wang et al. (2003) used cDNA microarray to examine the 
differences in gene expression in the cortex of rats exposed to a cat.  They used two 
different strains of rats that expressed different levels of anxiety when exposed to a 
cat.  Their results identified changes in expression levels of genes known to be 
involved in anxiety, such as GABA and 5-HT receptor subtypes, as well as genes so 
far unrelated to anxiety, such as fibroblast growth factor and the microtubule-
associated protein (Wang et al., 2003).   
In another study, Koks et al. (2004) used suppression subtractive 
hybridization to study the gene expression changes in the amygdala rats exposed to 
cat odor compared to untreated rats.  They also showed upregulation of genes 
known to be associated with anxiety, carboxypeptidase E which is involved in the 
synthesis of neuropeptides, and unique genes, such as melanocyte proliferating gene 
1 whose function is unknown (Koks et al., 2004).  While still in their early stages 
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new molecular techniques are enabling researchers to probe into the molecular 
workings of cells and systems with greater ease than ever before.  This has allowed 
research to go in new directions, independent of known drug mechanisms.   
1.6 Prion protein 
 
The term prion was first applied to a proteinacious factor associated with 
mammalian neurodegenerative disorders such as transmissible spongiform 
encephalopathies (Si et al., 2003).  A distinctive characteristic of these disorders is 
the presence of aggregates of protease-resistant proteins.  These proteins were 
discovered to be misfolded, protease-resistant, β-sheet–rich versions of the normal 
prion protein found in the host cell (Glatzel et al., 2005). The infectious, misfolded 
prion proteins recruit normal cellular prion proteins and cause them to switch from 
their normal conformation to the misfolded conformation (Glatzel et al., 2005; Si et 
al., 2003).   
In the beginning prion was a term only applied to the infectious mammalian 
prion protein.  Later, a handful of proteins were identified in yeast that exhibited 
numerous characteristics similar to the infectious prion protein although they had no 
significant sequence homology between them.  After the identification of the yeast 
prion proteins the definition of a prion protein changed (Wickner et al., 2004).  It no 
longer only applied to the proteinacious factor associated with mammalian 
neurodegenerative disorders. The term prion protein now refers to any protein that 
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can change its conformation and in turn impose the same conformational change on 
other proteins (Wickner et al., 2004).    
The discovery that prion proteins are not purely pathological fueled the 
search to determine the cellular role of prions.  The “benign” cellular form of the 
prion protein is expressed in neurons as a glycoprotein anchored to the outer cell 
surface of neurons (Glatzel et al., 2005; Nico et al., 2005; Roesler et al., 1999).  
While it has been found to be non-pathogenic in neurons its function in the cell is 
unclear.  Some of its hypothesized roles include a signal transduction molecule, a 
protease, a superoxide dismutase or a component in a signal cascade (Glatzel et al., 
2005).  While many roles have been suggested none have been adequately 
supported. 
There is some evidence that the cellular prion protein may modulate anxiety.  
It is highly expressed in the hippocampus (Roesler et al., 1999) and has been shown 
to influence excitatory neurotransmission in the hippocampus (Carleton et al., 
2001). Excitatory synaptic transmission increases in relation to the amount of prion 
protein expressed; the more protein the stronger the transmission (Carleton et al., 
2001).  Another study used prion protein knockout mice in an investigation of 
anxiety. The mice lacking the prion protein showed normal short- and long-term 
memory and had anxiety levels identical to controls (Roesler et al., 1999).  A later 
study showed that mice lacking the prion protein did have a stronger anxiety 
reaction, but only after acute stress (Nico et al., 2005).  Thus, the role of the prion 
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protein in anxiety is believed to be in modulating behavior in response to acute 
stress (Nico et al., 2005). 
 
1.7 Cytoplasmic Polyadenylation Element Binding Protein 
 
While investigating the relationship of the prion with anxiety, we became 
aware of other prion-like proteins and their possible roles in anxiety. The 
cytoplasmic polyadenylation protein was one such case.   
Yeast prions contain a glutamine or asparagine rich region in the N-terminal 
that has been shown to be critical to its prion behavior (Si et al., 2003). A neuronal 
protein in Aplysia californica, the cytoplasmic polyadenylation element binding 
protein (CPEB), was also found to contain this unique N-terminal region (Si et al., 
2003).  Further investigation revealed other prion-like characteristics. In its prion 
conformation or “state” the CPEB protein is able to convert other CPEB proteins to 
the prion state without the assistance of any other outside factors (Si et al., 2003).  
CPEB was also shown to be more active, resulting in increased polyadenylation, 
while in its active prion state.  This self-perpetuating, highly active characteristic of 
Aplysia CPEB has been hypothesized to play an important role in synapse-specific 
plasticity, a mechanism important for learning, memory (Si et al., 2003). 
Learning and memory are key components of anxiety disorders.  Modulation 
of synaptic plasticity is believed to be the neural basis of learning and memory. 
Therefore the cellular control of synaptic plasticity could be an important area of 
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study into anxiogenesis. The long-term maintenance of synaptic plasticity has been 
shown to require the synthesis of new proteins at an activated synapse (Huang et al., 
2002; Wells et al., 2001; Wu et al., 1998).  But how the translation of specific 
mRNAs within an activated synapse was controlled was unknown.  The search to 
find a mechanism that could guide specific protein translation turned to developing 
Xenopus eggs.   
Oocytes inherit a large amount of maternal mRNA that remains dormant in 
the cytoplasm until a signal triggers their translation.  The maturation of oocytes and 
the early embryonic stages after fertilization are dependent on the translation of 
these dormant maternal mRNAs (Richter, 1999; Welk et al., 2001). Somehow these 
mRNAs were translated in not only a time-specific manner but also a location- 
specific manner.  This triggered translation is not a global event, but occurs with 
different mRNAs at different times.  
 Nearly all mRNAs receive a polyA tail in the nucleus as part of mRNA 
processing.  PolyA tails are hypothesized to stabilize mRNAs and protect them from 
degradation after they enter the cytoplasm. Within the nucleus the mRNAs are 
cleaved and then a polyA tail is added.  These two reactions require the cleavage 
and polyadenylation specificity factor (CPSF) to bind to a cis-acting element (a 
short, specific sequence of nucleotides within the mRNA itself) called the 
hexanucleotide.  The hexanucleotide is located in the 3-prime untranslated region 
(3´-UTR) and has the sequence AAUAAA. The bound CPSF interacts with a polyA 
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polymerase (PAP) to add the polyA tail.  The mature mRNAs are transported to the 
cytoplasm where they may be translated into proteins.   
Within the cytoplasm not all mRNAs are immediately translated.  In the 
oocytes certain mRNAs were found to have their polyA tails shortened and held 
dormant in the cytoplasm.  Later, just prior to translation, these same mRNAs had 
their polyA tails lengthened (Dickson et al., 2001; Richter, 1999).  These unique 
mRNAs were found to have two sequences in their 3´-UTR that targeted them for 
this polyadenylation event within the cytoplasm.  The first is the same cis-acting 
element required for nuclear polyadenylation, the hexanucleotide.  The second cis-
acting element resides approximately 20 nucleotides upstream of the hexanucleotide 
and is called the cytoplasmic polyadenylation element (CPE).  The CPE has the 
sequence UUUUUAU.  These two sequences allow the mRNA to be bound by 
numerous trans-acting factors that are responsible for the cytoplasmic 
polyadenylation.  Trans-acting factors are regulatory elements, usually proteins, 
which bind cis-acting elements in a sequence specific manner. 
Within the cytoplasm the CPE sequence is bound by the cytoplasmic 
polyadenylation element binding protein (CPEB).  It recruits the CPSF to the 
hexanucleotide sequence (Figure 1.1).  CPSF then brings in the PAP to catalyze the 
polyadenylation (Huang et al., 2002).   
 As previously mentioned, not all mRNAs targeted for polyadenylation do so 
at the same time.  The mRNAs must be held dormant in the cytoplasm.  Instead of 
requiring an entirely separate mechanism, CPEB also acts as a repressor of 
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translation.  In its dormant state CPEB bound to the CPE associates with another 
protein, maskin.  Maskin binds the cap binding factor eIF4E.  This prevents the 
interaction of eIF4E with eIF4G and the docking of the 40S ribosomal subunit 
(Huang et al., 2002).  The maskin-CPEB interaction prevents the assembly of the 
ribosome, preventing the translation of mRNA.  Thus the dormant form CPEB 
functions as a translational repressor.  
  A phosphorylation event triggers the conversion of CPEB from its repressive 
form to the form that catalyzes polyadenylation.  CPEB becomes phosphorylated by 
the serine/threonine kinase, Aurora A kinase.  The phosphorylation event allows the 
association of CPEB with CPSF.  It is believed that the polyadenylation causes 
maskin to dissociate from eIF4E.  This allows the eIF4E-eIF4G interaction and the 
docking of the 40S ribosomal subunit.  The mRNA is then translated (Huang et al., 
2002).  Cytoplasmic polyadenylation is a tight and elegant mechanism for 
translational regulation.  It allows specific mRNAs to be translated in a temporal- 
and spatial-specific manner based on the modification of the polyA tail.   
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Figure 1.1:  Diagram of cytoplasmic polyadenylation, a mechanism conserved in
 both oocytes and neurons.  Signaling by either progesterone or NMDA
 receptor triggers phosphorylation of CPEB by Aurora Kinase, triggering
 polyadenylation (Huang et al., 2002) 
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1.7.1 CPEB in the Rodent Brain 
 
The adult rodent has borrowed a mechanism from development.  CPEB is 
indeed found in the adult brain of rodents.  It has been identified in the 
hippocampus, the cerebellum and the cerebral cortex.  More specifically, CPEB has 
been located in the dendritic layers of the hippocampus and synapses of cultured 
hippocampal neurons (Richter, 1999; Wu et al., 1998).   
Many components required for polyadenylation in Xenopus oocytes have 
been identified in the rodent brain.  CPEB, Aurora A kinase and maskin all have 
been found to be enriched in postsynaptic density compartments (Richter, 1999; Wu 
et al., 1998).  PAP, CPSF and eIF4E have also been found not only in the 
postsynaptic compartments but also in the cell body (Huang et al., 2002).  
This evidence suggests that CPEB-mediated cytoplasmic polyadenylation 
and translation can occur within dendrites (Huang, et al., 2002).  Experiments using 
dark-reared rats have confirmed CPEB-mediated polyadenylation and translation 
occurs in the synapses.  In response to exposure to light CPEB was found to be 
phosphorylated by a kinase downstream of the NMDA receptor.  This event resulted 
in the polyadenylation of the CPE containing Calcium/Calmodulin-dependent 
protein kinase II (CaMKII) mRNA, leading to its translation (Huang et al,. 2002; 
Wu et al., 1998).   These experiments have shown CPEB to function in the rodent 
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brain as a regulator of translation in a similar manner to that found in Xenopus 
oocytes.  
 
1.8 Project 
 
Deborah Finn has written that “genetic research on anxiety disorders will 
benefit from the continued investigation of the neural circuits involved in anxiety, 
allowing for the identification of candidate genes and proteins that is not just based 
on clinical observations of a therapeutic response” (Finn et al., 2003). This 
statement summarizes the aim of this project.  This project seeks to uncover some 
molecular mechanisms underlying anxiety that have been overlooked due to the 
focus of research on the mechanisms of known anxiolytics drugs.  
Pathological anxiety may be seen as an extreme expression of normal anxiety. It is 
likely that an alteration of a normal mechanism may be at the root of anxiety 
disorders. Perhaps within the brain certain molecular changes cause normal anxiety 
to become excessive and pathological.  We hypothesize inherent high- and low-
anxiety are caused by or accompanied with overexpression of a variety of genes in 
the amygdala, hippocampus, nucleus accumbens.  The purpose of this study is to 
examine changes in gene expression that may underlie inherent anxiety.  
Specifically, five objectives will be addressed in this project: 
1. To identify rats with inherently high or low levels of anxiety using 
the elevated plus maze;   
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2. To prepare two cDNA populations using the amygdala, hippocampus 
and nucleus accumbens isolated from high- and low-anxiety-like 
behavior rats; 
3. To identify genes upregulated in the two cDNA populations using the 
suppression subtractive hybridization technique; 
4. To manipulate CPEB protein expression by construction of vectors to 
over-express or knock down the CPEB protein;   
5. To examine the expression of the CPEB, its upstream effector, 
Aurora A kinase, and its downstream target, CaMKII, in the 
amygdala, hippocampus and nucleus accumbens of high- and low-
anxiety rats. 
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2 Methods 
 
 
2.1 Animal Model of Anxiety 
 
Male Wistar rats (250-280g) were used to model anxiety, as it has been 
reported that while identical in strain, sex and age, the anxiety-like behavior of 
individual Wistar rats can be different as measured by the EPM (Ho et al., 2002). 
These differences in anxiety measured in individual Wistar rats are repeated in other 
anxiety models and the anxiety levels measured by the EPM can also predict the 
behavior in other anxiety models (Ho et al., 2002).  Thus, they were the ideal rat 
strain to study inherent levels of anxiety. 
To establish the high- and low-anxiety experimental groups, the rats were 
tested using the standard EPM (Figure 2.1).  The maze dimensions were: arms 4.25” 
(10.80 cm) wide and 19.75” (50.17 cm) long, intersection 4.25” (10.80 cm) x 4.25” 
(10.80 cm), closed arm walls 15.75” (40.01 cm) high.  The maze was elevated 19” 
(50 cm) off the ground.   
Provisions were made to ensure consistency during behavioral testing. The 
maze was set in a closed room with fluorescent lighting.  It was centered so that no 
shadows were cast on the maze apparatus.  Each rat was handled 1 hour a day for 5 
days prior to testing to ensure any measured anxiety levels were not due to handling 
stress.  The rats were allowed to acclimatize to the testing room for half an hour 
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before testing.  The testing room was set up so there were no disruptions during 
testing.   
During the test a rat was placed in the intersection facing an open arm.  
Timers were started when the rat was released.  It was left undisturbed for 5 
minutes.  An arm entry was defined as all 4 feet having crossed the threshold of the 
arm. Time spent in the center intersection was not measured.  Total amount of time 
spent in either the open or closed arms was recorded by two people in the room; 
each was responsible for either the open or closed arms.  The maze apparatus was 
cleaned after every test with 95% ethanol and allowed to dry before a new rat was 
placed in the maze. 
 
 
 
Figure 2.1:  Example of Elevated Plus Maze
 Apparatus 
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2.2 Dissection of Rat Brain 
 
In accordance with a protocol approved by the University of Saskatchewan 
Animal Care and Use Committee, trained personnel anaesthetized rats with sodium 
pentobarbital (65mg/kg body weight) 1 week after behavioral testing.  The rats were 
then decapitated and the brain removed and the amygdala, hippocampus and nucleus 
accumbens immediately dissected.  Half of each brain sample was used immediately 
for poly[A+] RNA isolation.  The other half was frozen in liquid nitrogen and then 
stored at -80°C for later use.    
 
2.3 Isolation of poly[A+] RNA 
 
Total poly[A+] RNA was isolated using Oligotex mRNA kit (Qiagen Inc, 
Mississauga, On.).  The kit isolated mRNAs using a hybridization reaction between 
the polyA+ tails of the mRNAs and a dT oligomer attached to a solid particle.  The 
mRNAs were then bound in the solid phase while other cellular molecules, 
including rRNAs and tRNAs, remained in the liquid phase and were removed by 
discarding the supernatant. In this case the brain samples were homogenized and 
lysed in the presence of a highly denaturing guanidine-isothiocyanate (GITC) buffer 
to inactivate any RNases.  The Oligotex suspension was added to bind the mRNA.  
After the supernatant was washed away the pure mRNA content was eluted.  
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2.4 Conversion of mRNA to cDNA 
 
 
The isolated mRNA was converted to cDNA using the reverse transcription- 
polymerase chain reaction (RT-PCR) outlined in the BD PCR-Select™ cDNA 
Subtraction Kit User Manual (BD Biosciences Canada, Mississauga, ON).  The 
mRNA was converted to cDNA using AMV Reverse Transcriptase enzyme as 
described by the manual.  The double stranded cDNA was used directly in the 
suppression subtractive hybridization experiment.  
 
2.5 Confirmation of cDNA 
 
 
The cDNA samples were subjected to a test PCR to confirm the success of 
the RT-PCR to produce double stranded cDNA. Glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH) was used as a control for all the samples.  G3PDH was 
amplified via PCR using Pfu polymerase (Fermentas, Burlington, ON). The G3PDH 
primers synthesized by Invitrogen (Carlsbad, CA) had the following sequences: 
sense, 5´-ACCACAGTCCATGCCATCAC; antisense, 5´-
TCCACCACCCTGTTGCTGTA.  Pfu polymerase was added after the reaction had 
reached 94°C. The PCR cycle was as follows: 94°C for 40 seconds, 55°C for 30 
seconds, 72°C for 1 minute.  This cycle was repeated 35 times.  The PCR finished 
with an elongation period of 10 minutes at 72°C.  The PCR products were 
visualized via electrophoresis in a 1% agarose gel.   
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2.6 Suppression Subtractive Hybridization 
 
Suppression subtractive hybridization has become a popular method for 
studying differential gene expression in cells and tissues.  Through a series of 
hybridizations sequences only expressed in one population are isolated and 
identified.  In the past the traditional method of subtractive hybridization was 
inefficient at obtaining rare transcripts thus allowing many genes expressed at low 
levels go unidentified (Diatchenko et al., 1996; Gurskaya et al., 1996).  Recently a 
PCR based subtractive hybridization method was developed.  The PCR suppression 
step allows the amplification of differentially expressed target sequences while 
suppressing the non-target DNA (Diatchenko et al., 1996). 
 In suppression subtractive hybridization two populations of cDNA are 
compared against each other and genes expressed in the one population are isolated 
though two hybridization steps (Figure 2.2).  In the first step the tester cDNA 
population is divided into two populations.  Each population is ligated to one of two 
double stranded adaptors at their 5´ end.  The result is two unique tester sub-
populations: one sub-population with adaptor A and another with adaptor B.  Excess 
driver cDNA is added to each sample and allowed to hybridize.  Any common 
sequences between the tester and driver will form hetero-hybrids.  In the second step  
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Figure 2.2: Schematic of Suppression Subtractive Hybridization (Gurskaya et al., 1996).  Tester A
 and Tester B represent the tester population split into two subpopulations and each ligated
 to two unique adaptors.  Stage one represents the first hybridization, stage two, the second.
 The last section shows the possible combinations of tester and driver hybrids and their
 response to the PCR step.  
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the two subpopulations are added together and allowed to hybridize.  In this step the 
sequences unique to the tester will form homo-hybrids with a unique adaptor on 
each end.  At this stage PCR is used in a suppression step.  PCR is performed using 
primers complementary to the two adaptors.  This allows only sequences with both 
adaptors A and B to be exponentially amplified (Diatchenko et al., 1996; Gurskaya 
et al., 1996).  The result is a collection of sequences that are upregulated in only one 
population, the tester.   
 Here the high- and low- anxiety cDNA samples were compared using BD 
PCR-Select™ cDNA Subtraction Kit (BD Biosciences Canada, Mississauga, ON).  
Each library was used as both tester and driver in separate hybridizations to identify 
genes upregulated in each population. 
The cDNAs were digested with RsaI, as described in the protocol, to create 
blunt ended cDNAs.   Adaptors were ligated to the tester cDNAs.  In this case 
adaptors were ligated to both high- and low-anxiety in separated, parallel reactions.  
The hybridizations were also done in parallel with the high- and low-anxiety cDNAs 
acting as tester in separate reactions.  After the second hybridization the samples 
were amplified using the PCR protocol outline in the manual.  The differentially 
expressed genes were subjected to T/A cloning using the T-Easy vector of the p-
GEM T-easy vector system (Promega, Madison, WI) and used to transform 
competent cells as described in detail below.   
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2.7 Sequencing and Bioinformatics 
 
Successfully transformed bacterial clones, which were the result of the 
suppression subtractive hybridization experiment, were grown in 96-well plates in 
100µL Luria Broth for 12 hours.  The plasmids containing the differentially 
expressed cDNAs were both isolated and sequenced by the National Research 
Council’s Plant Biotechnology Institute (Saskatoon, SK). When the sequences were 
returned the sequence information was submitted to WorkBench 
(http://workbench.sdsc.edu/) to remove any remaining common sequences.  Open 
Reading Frame analysis was used to remove all non-coding fragments.  Finally, 
BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/) was used to identify gene 
names.  All structural and mitochondrial genes were removed.  The final list of 
genes was subjected to a literature search to identify any known relationship to 
anxiety.   
 
2.8 PCR for CPEB 
 
CPEB open reading frame was amplified from cDNA obtained from either 
PC12 cell or rat hippocampal cDNA using the polymerase chain reaction (PCR).  
The primers were synthesized by Invitrogen (Carlsbad, CA) and had the following 
sequences: Sense, 5´-AGATCTATGCTTTTCCCCACCTCTG;  
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anti-sense, 5´-GAATTCTTCTCCCTTGTCTGCAGAAAG.  The sense primer was 
designed to include a BglII restriction enzyme site, whereas the anti-sense primer 
included an EcoRI restriction enzyme site (underlined in sequence above) to be used 
for future sub-cloning into the pIRES2-EGFP vector.   
The CPEB sequence was amplified from PC12 cell cDNA using the primers 
described above and Pfu DNA polymerase. Pfu polymerase was added after the 
reaction had reached 94°C. The PCR cycle was as follows: 94°C for 40 seconds, 
55°C for 40 seconds, 72°C for 3 minutes.  This cycle was repeated 35 times.  The 
PCR finished with an elongation period of 10 minutes at 72°C.  
The full length CPEB sequence could not be obtained from rat hippocampal 
cDNA using the traditional method of using primers complimentary to the start and 
end of the gene. Using a modified protocol the gene was amplified in two halves, 
which were then used to create the full length sequence.   In the first reaction the 
sense primer was paired with the intermediate anti-sense primer complementary to 
the middle section of the CPEB sequence.  In a second reaction the anti-sense 
primer was paired with the intermediate sense primer complementary to the middle 
of the CPEB sequence.  The intermediate primer sequences were as follows: 
Intermediate sense, 5´- GTGTTAACCAATCCAAGCTTCTG; Intermediate anti-
sense, 5´-CAGAAGCTGGATTGGTTAACAC.   
The halves of the full CPEB sequence were amplified using Pfu polymerase 
to minimize the chance of mutations.  Pfu polymerase was added after the reaction 
had reached 94°C. The PCR cycle was as follows: 94°C for 40 seconds, 55°C for 1 
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minute, 72°C for 3 minutes.  This cycle was repeated 40 times.  The PCR finished 
with an elongation period of 10 minutes at 72°C.  
The two PCR reactions were then combined together and amplified using the 
sense and anti-sense primers (primers for the beginning and end of the cDNA) to 
obtain the full length sequence from the two halves.  The cycle conditions for the 
second round of PCR were identical to the above description except the cycle was 
repeated 30 times. To allow cloning into the T-Easy vector the full length 
hippocampal CPEB sequence was incubated in the presence of dATP and Taq 
polymerase (Invitrogen, Burlington, ON)  at 72°C for two hours to add terminal 5´ 
adenine overhangs to the sequence. The PCR products were then isolated on a 1% 
agarose gel and purified using the Wizard SV Gel and PCR clean-up system 
(Promega, Madison, WI). 
 
2.9 Ligation into T-Easy vector  
  
T/A cloning was used in the creation of the cDNA libraries (post-
suppression subtractive hybridization) and the initial cloning of the CPEB fragment.  
T/A cloning was performed using the T-Easy vector of the p-GEM T-easy vector 
system. Adenine bases (A) were added to the blunt ended cDNA to enable base 
pairing to the free thymine bases (T) in the T-easy vector.  The DNA fragments 
were incubated with the T-easy vector in the presence of T4 DNA ligase.  The 
ligation reaction was incubated at 22°C for 2 hours and then incubated for another 2 
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hours at 16°C.  The reaction was then placed in an 80°C water bath for 2 minutes to 
kill the ligase.  The T-Easy vector containing the insert of choice was then used to 
transform the DH-5α strain of competent E. coli cells as described in a later section.   
 
2.10 Selection of cells transformed with T-Easy vector 
 
 
The cells transformed with the T-easy vector were plated in the presence of 
ampicillin, isopropyl-beta-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-
3-indolyl-beta-D-galactopyranoside (X-GAL) (Fermentas, Burlington, ON) to 
identify colonies that were successfully transformed with the vector.  The T-easy 
vector not only confers ampicillin resistance but is also built to allow colorimetric 
identification via β-galactosidase activity.  The successfully transformed white 
colonies were then cultured in Luria Broth containing ampicillin (to maintain 
selection of the clone) at 37°C and shaking overnight.  The T-Easy vector was 
recovered from the cultures using the Promega Mini-prep kit (Madison, WI).  The 
vectors containing CPEB were digested with EcoRI and BglII (Fermentas, 
Burlington, ON) and run on a 1% agarose gel to confirm the presence of CPEB in 
the vector.  The CPEB fragment from one of the successful vectors was isolated, 
purified using the Wizard SV Gel and PCR clean up system (Promega, Madison, 
WI) and was sequenced for confirmation and to ensure no mutations were present. 
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2.11  Sub-cloning into pIRES2-EGFP 
 
 
 T-Easy vector containing CPEB was digested with EcoRI and BglII.  CPEB 
sequence was isolated on a 1% agarose gel and purified as described above.  The 
mammalian expression vector pIRES2-EGFP was also digested with EcoRI and 
BglII.  CPEB was ligated into pIRES2-EGFP using the following reaction: 1uL 10X 
ligation buffer, 7uL CPEB, 1uL pIRES2-EGFP, 1ul T4 DNA ligase.  The reaction 
was allowed to proceed at 25°C for 4 hours.  The DH-5α strain of E. coli was 
transformed as described below. In this instance colonies were plated with 
kanamycin as pIRES2-EGFP confers kanamycin resistance. The successful clones 
were confirmed through plasmid isolation and digestion as described above for the 
T-Easy vector.  
 
2.12  siRNA Design and pSilencer Construction 
 
 
Small interfering RNAs (siRNAs) are short RNA sequences that target 
specific mRNAs and prevent their translation.  The siRNAs are constructed to be 
complementary to the mRNA sequence.  The siRNA forms a double stranded 
molecule with the mRNA through hybridization.  The double-stranded RNA is then 
targeted by the cell’s own defense mechanism. The specific mRNA is degraded and 
its protein product reduced or eliminated completely (Elbashir et al., 2001).  
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Three unique siRNA sequences were designed against CPEB.  The 
sequences were built using siRNA target finder from GenScript 
(www.genscript.com/ssl-bin/app/rnai).  Ten sequences were generated against 
CPEB.  Three out of the original ten sequences were chosen using the siRNA design 
features outlined in Elbashir et al. (2001). The sequences were as follows (all 
sequences 5´-3´):   
1. CPEB-S1 sense: 
GATCCAACTGCAGATAAGACACAGAGTTGATATCCGCTCTCTGTG
TCTTATCTGCAGTTTTTCCAAA;  
2. CPEB-S1 anti-sense: 
AGCTTTTCCAAAAACTGCAGATAAGACACAGAGAGCGGATATCA
ACTCTGTGTCTTATCTGCAGTTG;  
3. CPEB-S2 sense: 
GATCCAAGCAGACCTGATCTCGGCTGTTGATATCCGCAGCCGAGA
TCAGGTCTGCTTTTTTTTCCAAA; 
4. CPEB-S2 anti-sense: 
AGCTTTTGGAAAAAAAGCAGACCTGATCTCGGCTGCGGATATCAA
CAGCCGAGATCAGGTCTGCTTG; 
5. CPEB-S3 sense: 
GATCCAAGTCACACGACCAGACCCAACCACACCTTGGGTCTGGTC
GTGTGACTTTTTTTCCAAA; 
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6. CPEB-S3 anti-sense: 
AGCTTTTGGAAAAAAAGTCACACGACCAGACCCAAGGTGTGGTT
GGGTCTGGTCGTGTGACTTG.   
The sequences were synthesized by Invitrogen (Carlsbad, CA).  Each siRNA 
sequence is complementary to a unique sequence within the open reading frame of 
CPEB.  Each sequence was designed with a BamHI and HindIII restriction site at 
either end to allow insertion into the pSilencer neo vector (Ambion Inc., Austin, 
TX). The sequences were annealed to their compliment and ligated into the 
pSilencer neo Vector according to the protocol described by Ambion Inc.  The stock 
pSilencer was previously modified with the insertion of two PstI sites to allow 
ligation of the siRNA inserts to be confirmed.  The ligated vector was used to 
transform the DH-5α strain of competent E. coli cells as described below.  The cells 
were plated in the presence of ampicillin overnight to screen for successfully 
transformed colonies. The plates were incubated at 37°C overnight.   The four 
randomly selected colonies were then cultured in Luria Broth in the presence of 
ampicillin (to maintain selection) at 37°C overnight.  The pSilencer vectors were 
recovered from the cultures using the Promega Mini-prep kit (Madison, WI).  The 
isolated vectors were digested with PstI and run on a 1% agarose gel to confirm if 
the siRNA inserts were present in the vectors.   
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2.13  Transformation of DH-5α strain of competent E. coli 
Cells 
 
 
DH-5α strain of competent E. coli cells were removed from -70°C freezer 
and placed directly on ice.  Twenty µL of selected plasmid was added to the cells 
and allowed to incubate on ice for 30 minutes.  The cells were then transferred to a 
42°C water bath for 1 minute and 30 seconds.  They were immediately returned on 
ice for 5 minutes and 400 µL SOC medium was added.  After the 5 minutes on ice 
the cells were incubated at 37°C for 30 minutes.  After the 30 minute incubation the 
cells were centrifuged at 5000 g for 5 minutes.  Most of the supernatant was 
removed leaving the cells to be resuspended in approximately 50 µL of media.  The 
cells were then spread on agar plates containing the appropriate selection 
components.  The plates were allowed to sit for 5 minutes prior to being placed in a 
37°C incubator overnight.    
 
2.14  Stable Transfection of PC12 cells 
 
 
 Rat phaeochromocytoma (PC12) cells were grown in DMEM media 
supplemented with 10% horse serum, 5% FBS, 25ug/mL penicillin, 25ug/mL 
streptomycin and 2.5 µg/mL Fungizone® Antimycotic (Invitrogen, Burlington, 
ON).  Flasks and plates were coated with rat-tail collagen.  Cells were incubated at 
37°C in 5% CO2.  Media was changed every 3 days.  For transfection cells were 
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plated at 2x105 on a 24-well plate in DMEM with serum 24 hours prior to 
transfection.  Plasmids to be transfected were diluted to 0.8 µg in DMEM.  
Lipofectamine 2000 (Invitrogen, Burlington, ON) was mixed with DMEM in a 
separate tube.  The plasmids were incubated in DMEM for 5 minutes at room 
temperature prior to combining with the Lipofectamine solution.  The DNA was 
incubated with Lipofectamine for 20 minutes at room temperature. One hundred µL 
of the DNA/Lipofectamine complex were added to each well.  After 48 hours of 
incubation the media was changed to the selection media that contained 400 µg/mL 
of G418, the selection agent.  The selection media was completely replaced every 3 
days for 3 weeks.  At this point the control cells had died and colonies began to 
appear only in transfected wells.  The selection media was then changed once a 
week for two weeks.  The cells were then transferred to P25 flasks and grown in the 
selection media until confluent. 
 
2.15  Preparation of Total Cell Lysate  
 
Frozen brain tissues were allowed to thaw on ice.  The samples were 
manually homogenized in RIPA buffer with protease inhibitor cocktail (1:100) 
(Sigma-Aldrich, Oakville, On.) on ice.  Cell culture samples were centrifuged at 
4000 g and the media removed.  The pellet was then washed 3 times in PBS and 
RIPA lysis buffer with protease inhibitor added after the last wash.  The samples 
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were incubated on ice for 30 minutes and then centrifuged at 14,300 g for 10 
minutes at 4°C.  The supernatant was collected and the pellet discarded.  
Total protein concentration was determined using the BCA Protein Assay kit 
(Pierce, Rockford, IL) before samples were used for immunoprecipitation or 
western blot. The samples were mixed with the working reagent in a 96-well plate 
and incubated at 37°C for 30 minutes. The samples were then cooled to room 
temperature prior to spectrophotometric analysis as described by the kit.  The 
samples were read at 562 nm. The concentrations of the brain samples were 
established by comparing their absorbances to a standard curve of known protein 
concentrations. 
 
2.16  Immunoprecipitation of Proteins 
 
The total protein of brain samples was diluted to 1µg per µL in RIPA buffer 
containing protease inhibitor.  One µg of specific antibody was added to every 
100µg of total protein and the samples were incubated at 4°C on a rocker for 2 
hours or overnight.  Sepharose Protein A (Rockland Inc., Philadelphia, PA) was 
added and the samples incubated for another hour rocking at 4°C.  The samples 
were centrifuged and the supernatant discarded.  The pellet was washed 3 times in 
cold PBS.  After the last wash the pellet was resuspended in SDS loading buffer and 
incubated in 95°C water bath for 5 minutes.  The samples were then centrifuged at 
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14,300 g for one minute. Each immunoprecipitation experiment was repeated 3 
times to ensure accuracy of the results 
 
2.17  Western Blot 
 
Equal total concentrations of protein sample were resolved by SDS-PAGE 
gel with a 4% stacking gel and 10% resolving gel at 120 V for 1 ½ hours. The 
proteins were then transferred to an Immun-Blot PVDF membrane (Bio-Rad, 
Mississauga, ON) at 0.22 A for 1 ½ hours.  After transfer the membrane was briefly 
washed for 30 seconds in TBST (1:1000 Tween 20 in TBS) to remove any transfer 
buffer. The membrane was then incubated in a blocking solution containing 5% 
instant skim milk powder in TBST for one hour.  The membrane was incubated in 
primary antibody (1:1000 anti-CPEB, anti-CaMKII or anti-Aurora A kinase; 
AbCam, Cambridge, MA) or 1:2000 anti-β-actin (Sigma-Aldrich, Oakville, ON) for 
2 hours at room temperature or overnight at 4°C.   The membrane was then washed 
for 3x5 minutes in TBST.  The membrane was incubated with HRP-conjugated 
secondary antibody (1:2000) at room temperature for 2 hours.  The membrane was 
washed in TBST as described above and then incubated for 1 minute in ECL™ 
Western Blotting Detection Reagent (Amersham Biosciences, Piscataway, NJ).  The 
membrane was exposed to X-Ray film (KODAK, New Haven, Conn.) for variable 
exposure times. Membranes were stripped, if required, in stripping buffer (2% SDS, 
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62.5 mM Tris-HCl, 100 mM –mercaptoethanol) for 1 hour at 60°C.  The membrane 
was washed for 3x10 minutes in TBST prior to blocking in milk solution. 
 
2.18  Analysis of Western Blot 
 
 
Western blot images were scanned into a computer.  Adobe Acrobat 
Photoshop® CS was used to analyze the images.  The images were inverted and a 
box drawn around the most intense band.  The mean intensity was measured using 
the histogram function.  This was repeated for all bands.  The area measured for all 
bands was fixed.  The background was measured and subtracted from the band 
means.  The band corresponding to the control sample was set to 100% and the 
intensity of the remaining bands was calculated relative to the control band.  The 
procedure was repeated for each replicate experiment and the mean of the relative 
intensities calculated and graphed using Microsoft Excel.  One-way AVOVA was 
used to determine any significant difference among control, high- and low-anxiety 
groups.    
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3 Results 
 
3.1 Elevated Plus Maze 
 
Rats were classified as high- or low- anxiety by the total amount of time 
spent in the closed or open arms respectively.  Fifty one rats in total were tested 
(Table 3.1).  The letters assigned to the groups indicate the day the group was tested 
together.  Out of the original 51 rats 2 showed high-anxiety.  Rat C1 spent 4 minutes 
29 seconds exploring the closed arms and only 8 seconds in the open arms. Rat C4 
spent 4 minutes and 23 seconds in the closed arms and 15 seconds in the open arms.  
Three rats showed low-anxiety. Two were chosen for further experiments to match 
the number of high-anxiety rats. Rat A9 spent 4 minutes 14 seconds in the open 
arms and no time in the closed arms.  Rat A12 spent 3 minutes 46 seconds in the 
open arms and 24 seconds exploring the closed arms.   Two rats labeled by the # 
symbol were eliminated from the experiments. Rat D4 was deemed unsuitable as it 
froze in the middle of an open arm and remained immobile for the entire 5 minute 
testing period.  Another rat (number C11) was deemed unsuitable because it fell off 
the open arm during testing. Four controls were chosen out of the remaining rats 
(numbers A2, A5, A10 and D3).  The 4 controls spent equal amounts of time in both 
the open and closed arms.  
The rats spent a higher amount of time exploring the open arms than 
expected.  A possible explanation for this is that the two people observing the test 
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were seated in the same testing room and were a few feet away but in line with the 
open arms.  As the rats were previously handled by these two observers their 
presence may have inadvertently decreased the anxiogenic properties of the open 
arm. Also, the high-anxiety rats were identified on the same day while the low-
anxiety rats were also identified on the same day (although not the same day as the 
high-anxiety rats).  This clustering may indicate that there was an unknown factor 
influencing the behavior of the rats on each day.  To ensure the test days did not 
influence the overall “emotionality” of the entire group of rats and introduce a bias a 
statistical analysis was performed on the results from groups A and C.  The control 
rats from days A and C were compared to each other using Student’s t-test.  The 
statistic analysis showed no significant difference between the control times 
between the two days (P < 0.05, df =10, t = 1.7046).  Thus, there appears to be no 
underlying factor which caused group A to have lower anxiety and group C to have 
higher anxiety in general.  The difference in anxiety levels of rats A9, A12, C1 and 
C4 were specific to the individuals not the group.      
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Rat C O Rat C O Rat C O Rat C O 
A1 2:22 2:02 B1 2:52 1:01 C1* 4:29 0:08 D1 2:56 1:31 
A2 2:06 2:04 B2 1:27 2:45 C2 3:10 0:57 D2 3:38 0:49 
A3 3:11 1:09 B3 2:28 1:39 C3 2:37 1:20 D3 2:06 2:15 
A4 1:31 2:36 B4 1:13 3:04 C4* 4:23 0:15 D4# 0 5:00 
A5 2:05 2:20 B5 1:16 2:44 C5 3:01 1:05 D5 3:29 0:45 
A6  0:09 3:33 B6 1:25 2:22 C6 3:26 1:09 D6 2:35 1:23 
A7 1:59 2:28 B7 1:09 2:58 C7 1:37 2:42 D7 3:19 0:07 
A8 1:17 2:46 B8 1:14 2:35 C8 3:01 0:56 D8 3:11 1:13 
A9* 0 4:14 B9 1:56 2:21 C9 2:25 1:33 D9 2:15 1:24 
A10 2:06 2:03 B10 1:53 2:18 C10 2:47 0:48 D10 2:55 0:53 
A11 2:19 1:33 B11 3:03 1:01 C11# 3:29 1:10 D11 3:55 0:30 
A12* 0:24 3:46 B12 1:09 2:47 C12 3:36 0:38 D12 3:29 0:51 
A13 1:24 2:40 B13 2:38 1:02 C13 2:32 1:54    
Table 3.1: Total Closed (C) and Open arms (O) times for Elevated Plus Maze. 
(*denotes rats chosen for further experiments. # denotes rats rejected from study due to their 
unconventional behavior during testing) 
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Figure 3.1: PCR of G3DPH as a control for cDNA samples.  
M: 1 Kb DNA ladder 
H1 & H2: High-anxiety cDNA. 
L1 & L2: Low-anxiety cDNA. 
C1 & C2: Control cDNA
3.2 Anxiety Related Genes 
 
Total polyA+ RNA was isolated from the brain samples containing the 
amygdala, hippocampus and nucleus accumbens dissected from the high- and low-
anxiety rats.  The polyA+ RNA was converted to cDNA via RT-PCR as outlined in 
the methods.  To ensure the RNA samples were successfully converted to cDNA the 
control, high- and low-anxiety cDNA samples were subjected to PCR of 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) as a control (Figure 3.1).  All 
of the samples showed a band indicative of G3PDH and were all of equal intensity.  
This showed consistency and completeness of the polyA+ RNA samples and their 
successful conversion to cDNA. The samples, therefore, were suitable for further 
experimentation.   
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Once the cDNA populations from the high- and low-anxiety samples were created 
and confirmed, they were used in suppression subtractive hybridization.  The goal 
was to identify genes upregulated in high-anxiety compared to low-anxiety and low 
compared to high.  
The final step of suppression subtractive hybridization is a PCR 
amplification of the remaining, and therefore upregulated, cDNAs.  These cDNAs 
were cloned as described above and then sent for sequencing.  The sequencing data 
returned 1000 genes in total that were found to be upregulated in either library. An 
exampled of the sequence data obtained is presented in Figure 3.2. 
To obtain a more manageable list of genes, bioinformatic analysis was 
employed.  First, all common and non-coding sequences were removed.  Next, the 
gene names were identified using BLAST analysis.  Lastly, all structural and 
mitochondrial genes were manually removed to condense the list.  After all 
bioinformatic analysis the candidate gene list was comprised of 104 low-anxiety 
genes and 67 high-anxiety genes.  The final list is presented in Table 3.2.   
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Figure 3.2: Representation of Sequencing Data: Partial sequence of Rattus norvegicus ribosomal
 protein s25 (upregulated in high-anxiety). 
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Table 3.2: List of Low- and High-Anxiety genes identified using Suppression Subtractive
 Hybridization.  All sequences from Rattus norvegicus unless otherwise noted. 
 
Low-Anxiety Genes 
1. AJ011971.1|MMU011971 M. musculus mRNA for wolframin 
2. NM_007459.2|  M. musculus adaptor protein complex AP-2, alpha 2 subunit 
(Ap2a2) 
3. AY004289.1| profilin II  
4. BC018374.1|M. musculus cysteine and histidine-rich domain (CHORD)-
containing,zinc-binding protein 1 
5. BC061534.1| clusterin 
6. M34043.1|RATROSB4T thymosin beta-4  
7. NM_009871.2|  M. musculus cyclin-dependent kinase 5, regulatory subunit (p35) 1  
8. AF439750.1| myelin basic protein (Mbp)  
9. XM_233556.3 serine/arginine repetitive matrix 1 (predicted) 
10.  AB045983.1|   M. musculus gene for gliacolin, complete cds 
11. AY255791.1| NDRG4-A1  
12. X13933.1|RNRCM1 calmodulin (pRCM1)  
13. BC061962.1| reticulocalbin 2 
14. NM_019299.1|  clathrin heavy polypeptide (Hc) (Cltc) 
15. M88469.1|RATFSAA f-spondin 
16. NM_014991.3| H. sapiens WD repeat and FYVE domain containing 3 (WDFY3), 
transcriptvariant 1  
17. BC020359.1|  M. musculus Nedd4 family interacting protein 1 
18. BC061721.1| vacuole Membrane Protein 1 (VMP1) 
19. NM_020610.1| M. musculus nuclear receptor interacting protein 3 (Nrip3) 
20. BC048929.1| M. musculus dystonin 
21. BC051641.1|  M. musculus tousled-like kinase 1 
22. NM_012505.1| ATPase, Na+K+ transporting, alpha 2 polypeptide (Atp1a2) 
23. AF332142.1|AF332142 chloride ion pump-associated 55 kDa protein (Clp55)  
24. BC058492.1|  heat shock 10 kDa protein 1 
25. BC060951.1|M. musculus NADH dehydrogenase (ubiquinone)1,alpha/beta 
subcomplex,1 
26. NM_004430.2| H. sapiens early growth response 3 (EGR3) 
27. AF234179.1|AF234179 M. musculus RNA-binding protein (Tbrbp)  
28. NM_057119.1| splicing factor, arginine/serine-rich 10 (transformer 2 Drosophila 
homolog) 
29. BC061536.1| serine (or cysteine) peptidase inhibitor, clade I, member 1 
30. AF254801.1|AF254801 brain-enriched SH3-domain protein 
31. BC060587.1|   lactate dehydrogenase A 
32. XM_341249| 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like 
protein homolog 1 (C. elegans)(predicted)  
33. BC022954.1|  M. musculus synapsin I 
34. XM_215227.3 similar to Eso3 protein 
35. NM_001005554 transmembrane 9 superfamily member 2 (Tm9sf2) 
36. BC024759.1|   M. musculus glycoprotein m6a  
37. AY324140.1| gap junction membrane channel protein alpha1 (Gja1) 
38. BC034586.1|  M. musculus ATPase, Na+/K+ transporting, beta 2 polypeptide 
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39. BC054811.1|  M. musculus myotrophin 
40. BC063081.1|  M. musculus copine IV  
41. BC061760.1|  ras homolog gene family, member Q 
42. M11942.1|RATHSPA  70 kd heat-shock-like protein 
43. NM_001006963   integral membrane protein 2B (Itm2b), 
44. U30938.1|RNU30938 microtubule-associated protein 2 (MAP2)  
45. BC060177.1| M. musculus putative homeodomain transcription factor 1 
46. NM_004028.3  H. sapiens aquaporin 4 (AQP4), transcript variant b  
47. L16532.1|RATCNPII  2',3'-cyclic nucleotide 3'-phosphodiesterase  (CnpII)  
48. J04828.1|RATASPEC nonerythroid alpha-spectrin gene, 3’ ennd 
49. AF151813.1|AF151813 H. sapiens CGI-55 protein  
50. NM_001008519| leucine-rich PPR-motif containing (predicted) 
51. XM_238280.3 START domain containing 7 (predicted) 
52. BC059146.1| transforming growth factor beta 1 induced transcript 4 
53. BC052427.1|  M. musculus GPI-anchored membrane protein 1  
54. BC003894.1|  M. musculus mortality factor 4 like 1  
55. BC061755.1| SPARC-like 1 (mast9, hevin) 
56. NM_001004224 similar to B-cell receptor-associated protein 31  
57. BC057390.1| H. sapiens Ras-induced senescence 1 
58. AE008684.1|AE008684 M. musculus T-cell receptor alpha/delta locus  section 2 of 
4 of the complete region 
59. AJ428213.1|RNO428213 heat shock protein 86 
60. BC008129.1|M. musculus 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide 
61. AJ001320.1|RNMUPP1 multi PDZ domain protein 
62. BC061877.1| glutamate oxaloacetate transaminase 1 
63. NM_009157.2| M. musculus mitogen activated protein kinase kinase 4 (Map2k4) 
64. NM_008974.3 M. musculus protein tyrosine phosphatase 4a2 (Ptp4a2) 
65. AB113399.1|  rCNR gene for cadherin-related neuronal receptor 
66. M38061.1|RATAMPASGB glutamate receptor (GluR-B) 
67. BC063164.1|  voltage-dependent anion channel 2 
68. X59993.1|RNZFP  putative zinc finger protein 
69. U67874.1|MMU67874 M. musculus fat facets homolog (Fam)  
70. AB091532.1|  M musculus Sema6D-1 mRNA for semaphorin 6D-1  
71. BC004671.1| M. musculus FK506 binding protein 1a 
72. XM_214996.3 embryonic ectoderm development (predicted)  
73. BC023864.1| M. musculus ARP2 actin-related protein 2 homolog (yeast) 
74. BC019118.1|  M. musculus RAB6, member RAS oncogene family 
75. XM_214099.3| similar to small unique nuclear receptor co-repressor (predicted) 
76. U35246.1|HSU35246 H. sapiens vacuolar protein sorting homolog h-vps4 
77. M63485.1|RATMATRIN3 matrin 3 
78. X15635.1|RNSR2CA sarcoplasmic reticulum 2+-Ca-ATPase 
79. XM_216717.3  FK506 binding protein 3 (predicted)  
80. S63233.1|S63233 phosphoglycerate mutase type B subunit  
81. BC056345.1|  M. musculus abl-interactor 2  
82. X87157.1|RNRNANE neurotensin endopeptidase 
83. BC063085.1| M. musculus DIX domain containing 1 
84. BC042568.1|  M. musculus WD repeat domain containing 2 
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85. AF271786.1|AF271786 fibroblast growth factor 13 (Fgf13) 
86. NM_022695.1|   neurotensin receptor 2 (Ntsr2) 
87. NM_177420   M. musculus phosphoserine aminotransferase 1 (Psat1) 
88. BC058083.1|  M. musculus sodium channel, voltage-gated, type III, beta 
89. NM_001009264  T-cell activation protein (Pgr1) 
90. XM_343513.2| amyloid beta (A4) precursor-like protein 2 (Aplp2) (predicted) 
91. M31178.1|RATCALBD28  calbindin D28  
92. BC058132.1| epididymal secretory protein 1 
93. U21955.1|RNU21955  tyrosine kinase receptor Ehk-3, truncated form 
94. NM_033566.1| M. musculus AT rich interactive domain 1A (Swi1 like) (Arid1a) 
95. AK078541.1| KARP-1-Binding protein 2 (KAB2) homolog [H. sapiens] 
96. AY358097.1| H. sapiens clone DNA21624 phosphodiesterase Hl  
97. AF106944.1|AF106944 PRx III (PRx III) 
98. BC021374.1|  M. musculus heterogeneous nuclear ribonucleoprotein D-like 
99. NM_021518.2| M. musculus RAB2, member RAS oncogene family (Rab2), mRNA 
100. XM_226278.3| similar to HBxAg transactivated  protein 2 (predicted) 
101. BC011279.1| M. musculus RAP1, GTP-GDP dissociation stimulator 1 
102. XM_235480.3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (predicted)  
 
       High- Anxiety genes 
1. NM_001024864 leucine zipper domain protein  
2.  NM_012628.1| protein kinase C, gamma, (Prkcc)  
3.  NM_001005528| ribosomal protein s25 (Rps25) 
4. X80029.1|RNHEM2   Hem-2 mRNA  
5. X93208.1|RSPNRD2  NRD2 convertase 
6.  AF372834 synaptic vesicle protein 2B (Sv2b)  
7. X07729.1|RNEN4 gene encoding neuron-specific enolase 
8. BC012862.1| M. musculus DEAD (Asp-Glu-Ala-Asp) box polypeptide 48   
9. BC024706.1| M. musculus gamma-aminobutyric acid (A)receptor-associated 
protein-like 1  
10. Y13380.1|RNAMPH2 amphiphysin (amph2) 
11. AJ278701.1|RNO278701 cytosolic branched chain aminotransferase (Bcatc gene) 
12. AY040224.1| H. sapiens AngRem46  
13. BC063162.1| eukaryotic translation elongation factor 1 alpha 1  
14.  NM_001004212| similar to N33 protein  
15. L05435.1|RATSV2AA synaptic vesicle glycoprotein 2a (Sv2a) 
16. AF007758.1|AF007758  synuclein 1 
17.  XM_225856.3| similar to Da1-6 (predicted) 
18. AY241868.1|   M. musculus chemokine-like factor superfamily 6  
19. BC061546.1| activating transcription factor ATF-4   
20. X66531.1|RNACHRA nicotinic acetylcholine receptor delta-subunit 
21.  XM_213650.2| Down syndrome critical region gene 5 (predicted)  
22. AF190991.1|AF190991 M. musculus clone MNCb-1314 chimeric Ttyh1 protein  
23. AF212861.1|AF212861 membrane interacting protein of RGS16 (Mir16)  
24. BC059130.1|  glutathione S-transferase, mu type 3  
25.  NM_013113.1| ATPase Na+/K+ transporting beta 1 polypeptide (Atp1b1) 
26. U03414.1|RNU03414 neuronal olfactomedin-related ER localizedprotein 
(D2Sut1e)  
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27. AY011335.1|  amyloid beta precursor protein (App)  
28.  XM_215251.3| zinc finger protein 216 (predicted)  
29. BC036717.1| M. musculus, Similar to reticulon 3, transcript variant 4 
30. BC031192.1| M. musculus BTB (POZ) domain containing 1   
31. X14159.1|RN2APHOS protein phosphatase-2A catalytic subunit  
32. X52817.1|RSC113  C1-13 gene product 
33. XM_214911.2| programmed cell death 5 (predicted)  
34. U58829.1|RNU58829 ferritin-H subunit  
35. NM_012495.1|  aldolase A (Aldoa) 
36.  BC061737.1| stearoyl-Coenzyme A desaturase 2 
37. M20246.1|RATALBA3  transthyretin gene, exon 4  
38.  NM_001009622| SAR1a gene homolog 2 (S. cerevisiae) (predicted)  
39. BC005490.1| M. musculus amyloid beta (A4) precursor protein  
40. BC003421.1| M. musculus ATPase, H+ transporting, V1 subunit E isoform 1 
41. U60579.1|RNCAII9   carbonic anhydrase II gene, 3' flanking sequence  
42.  NM_001005547 transmembrane 4 superfamily member 8 (Tm4sf8) 
43. BC062013.1| pleiotrophin   
44. AF452728.1| synaptogenesis-related mRNA sequence 7, 3'untranslated region 
45. AY035551.1| brain Ntab  
46. BC027769.1| M. musculus RAB15, member RAS oncogene family 
47. BC025597.1| M. musculus calcium/calmodulin -dependent protein kinase II gamma   
48. BC026538.1| M. musculus stathmin-like 2 
49.  BC051053.1| M. musculus RAS-related C3 botulinum substrate 1 
50. BC026550.1| M. musculus protein kinase inhibitor, gamma 
51. NM_001004080 gelsolin (Gsn) 
52. RAT1433PZI  14-3-3 protein zeta isoform mRNA, 3' end 
53.  NM_001008279  flightless I homolog (Drosophila) (predicted) 
54. M84725.1|RATNP25GN neuronal protein (NP25)  
55.  NM_001033680 synaptotagmin 1 (Syt1) 
56. AB095364.1| ank-s mRNA for ankyrin repeat small protein  
57. D37951.1|RATMIBP1 MIBP1 (c-myc intron binding protein 1) 
58. NM_012631.2| prion protein (Prnp) 
59. NM_024287.2| M. musculus RAB6, member RAS oncogene family (Rab6) 
60. AF347688.1|AF347681S9   M. musculus chloride channel isoforms (Clcn3) gene  
61. BC058485.1| calmodulin 2 
62. AY180177.1|M. musculus KIS kinase (Kis) gene 
63. X01964.1|RNLADEH1 lactate dehydrogenase  
64. U49062.1|RNU49062 heat stable antigen CD24  
65. NM_013053.1|  tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, theta polypeptide (Ywhaq)              
66. L17127.1|RATRN3 proteasome RN3 subunit  
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3.3 Prion Protein  
 
After the final candidate list was completed a detailed literature search was 
started to link any of the candidate genes to anxiety.  The gene for the prion protein 
(accession number NM_012631.2, #58 Table 3.2) was found to be upregulated in 
high-anxiety when compared to low-anxiety.  This result is in agreement with the 
previous findings of the modulating role of prion protein in anxiety in response to 
acute stress (Nico et al., 2005) as described in detail in section 1.6. 
 
3.4 Selection of Candidate Gene 
 
One gene from the list generated by the suppression subtractive 
hybridization was to be selected for further, more detailed examination.  Learning of 
the relationship of the prion protein with anxiety, we became interested in exploring 
other prion-like proteins even without direct evidence in supporting their role in 
anxiety. After a search of the available literature we were primarily interested in the 
prion-like protein CPEB for reasons described in section 1.7. 
 
3.5 PCR of CPEB 
 
To confirm the presence of CPEB in the rat hippocampus and PC12 cells, 
the full sequence of CPEB was amplified from cDNA from both samples.  In PC12 
cells the full-length sequence of CPEB was successfully amplified in one step 
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(Figure 3.3). One-step PCR, however, could not amplify the full-length sequence of 
CPEB from the rat hippocampal cDNA.  To obtain the complete sequence of the 
hippocampal CPEB, the two halves of the sequence were amplified separately and 
then the complete sequence was created by amplifying the two halves together 
(Figure 3.3).  The PCR for the full sequence resulted in two fragments of similar 
size.  The larger band of approximately 1400 bp (Figure 3.3) was isolated and 
sequenced (Figure 3.4).  BLAST analysis found it to be 100% identical to the 1442 
bp rat CPEB sequence.  Thus, CPEB transcripts were confirmed to be present in the 
adult rat hippocampus and PC12 cells. 
 
 
 
Figure 3.3: Agarose gel of PCR for CPEB using 1 Kb DNA ladder. 
 i) PCR of full length CPEB from PC12 cDNA  
ii) PCR of CPEB halves from hippocampal cDNA (left band represents
  the upstream half) 
iii) PCR of full length CPEB from hippocampal cDNA (arrow denotes
  fragment isolated for sequencing). 
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Figure 3.4: Nucleotide sequence obtained using PCR corresponding to the CPEB
 open reading frame. The sequence is 1442 bp long.  Shaded areas denote
 PCR primer locations: 1, sense primer; 2 and 3, Intermediate sense and anti
 sense primers; 4, anti-sense primer.  
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3.6 Expression of CPEB in Mammalian Cells 
 
 
3.6.1 Creation of pIRES2-EGFP-CPEB vector 
 
 
The full length CPEB sequence was inserted into the T-easy vector.  The 
vector was used to transform competent E. coli cells.  CPEB was confirmed to be 
inserted into both of the isolated T-easy vectors by restriction digest (Figure 3.5).  
The isolated CPEB fragment was then digested to create stick ends compatible with 
the pIRES2-EGFP vector and ligated into the digested vector.  The pIRES2-EGFP-
CPEB plasmid was designed to over-express the CPEB protein in mammalian cells.  
The pIRES2-EGFP-CPEB plasmid was isolated and digested to confirm CPEB 
insertion.  CPEB was found to be successfully inserted into only one of two clones 
(Lane 5, Figure 3.6).   
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Figure 3.6: Digest of pIRES2-EGFP containing CPEB.  
M: 1 Kb Plus DNA Ladder 
Lane 1: Empty pIRES2-EGFP undigested.  
Lane 2: Undigested pIRES2-EGFP-CPEB (clone 1).  
Lane 3: Undigested pIRES2-EGFP-CPEB (clone 2).  
Lane 4: EcoRI and BglII digested pIRES2-  
  EGFP-CPEB (clone 1). 
Lane 5: EcoRI and BglII digested pIRES2-  
  EGFP-CPEB (clone 2). 
 
Figure 3.5: Digest of T-Easy containing CPEB.  
M: 1 Kb Plus DNA ladder 
Lane 1: Undigested Plasmid. 
Lane 2: EcoRI and BglII digested plasmid 
(clone 1). 
Lane 3: EcoRI and BglII digested plasmid 
(clone 2). 
 61
 
3.6.2 siRNA Development   
 
Three siRNAs were synthesized to knock down CPEB protein expression. 
Each was inserted into a modified pSilencer vector and used to transform competent 
E. coli cells.  The pSilencer vector was isolated from four bacterial cultures per 
siRNA sequence.  The vector was digested with PstI.  Insertion of the CPEB 
fragment eliminates a second PstI site on the vector so that a successful ligation 
should result in only one band.  siRNA sequences S2 and S3 yielded single bands 
but siRNA sequence S1 yielded two bands (Figure 3.7).  This confirms the proper 
ligation of the siRNA S2 and S3 sequences into the pSilencer vector but not siRNA 
sequence S1.  This has been attributed to a base mismatch in the S1 siRNA 
sequence itself.  Therefore, siRNA sequences S2 and S3 were used for further 
experiments while S1 was discarded. 
 
 
 
Figure 3.7: Digest of pSilencer vector containing siRNA sequences.  
M: 1 Kb Plus DNA ladder.  
Lanes 1-4: siRNA sequence S1.  
Lanes 5-8: siRNA sequence S2.  
Lanes 9-11: siRNA sequence S3.  
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3.6.3 Transfection of PC12 cells  
 
 
PC12 cells were transfected with the pIRES2-EGFP-CPEB plasmid and 
pSilencer plasmid carrying either the siRNA S2 or S3 sequences.  Stable cell lines 
were established for all three plasmids. Samples of the transfected cells were 
subjected to a western blot against CPEB to determine their efficiency.  The 
pIRES2-EGFP-CPEB plasmid was expected to over-express CPEB while the 
siRNAs were expected to knockdown CPEB expression, relative to control cells.  
As can be seen in Figure 3.8 the pIRES2-EGFP-CPEB vector did not over-express 
CPEB, nor did the siRNAs knockdown CPEB over control cells. These preliminary 
results were not promising.   
 
Figure 3.8: Western Blot of Transfected PC12 cells. 
 Lane1: Control PC12 Cells 
 Lane 2: PC12 cells transfected with pIRES2-EGFP-CPEB 
 Lane 3: PC12 cells transfected with siRNA S2 sequence 
 Lane 4: PC12 cells transfected with siRNA S3 sequence 
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The goal of building the pIRES2-EGFP-CPEB plasmid and the siRNA 
plasmids was to obtain a method of manipulating CPEB expression in the rat in 
vivo.  The cell culture transformation was to confirm the desired activity of the 
plasmids before they were to be used in vivo.  As CPEB was found to be in low 
concentrations in our brain samples (see below) it is believed to only present in 
significant amounts in the hippocampus.  Therefore to make significant impact on 
its expression in vivo we would have had to inject the plasmids into the ventral 
hippocampus.  This brain region is large and thus injection of the CPEB plasmids 
into the ventral hippocampus would not be efficient.  Due to this limitation the 
development of plasmids to manipulate CPEB expression was stopped. 
 
3.7 Protein Expression of CPEB in Control, High- and
 Low-anxiety brain tissue  
 
To understand if CPEB had a role in anxiety, its protein expression was 
examined.  The protein expression of CPEB in high- and low-anxiety compared to 
control was investigated using western blot analysis of the brain samples obtained 
from the elevated plus maze results. In initial western blot experiments CPEB 
protein expression resulted as very faint bands (Figure 3.9).  To ensure that the faint 
bands were not the result of an error in the western blot protocol, the procedure was 
repeated with a PC12 sample as a control.  Low protein loading was also ruled out 
by stripping the membranes and re-probing them with β-actin antibody. The β-actin 
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antibody resulted in strong bands of equal intensity in all lanes (Figure 3.9).  The 
PC12 control cells also showed a relatively strong band specific for CPEB.  Thus, it 
appeared that the weak bands were the result of the CPEB protein being in low 
concentrations in the brain samples examined. This could be the result of 2 factors: 
(1) while CPEB is enriched in the hippocampus, the brain samples examined also 
included the amygdala and nucleus accumbens that contain very low concentrations 
of the CPEB (Huang et al., 2002; Wu et al., 1998); and (2) while the CPEB is 
concentrated in the post-synaptic density but not in other components of a neuron 
(Huang et al., 2002), the brain samples studied contained all the components of 
neurons.  To overcome this problem, an immunoprecipitation protocol was used to 
concentrate the amount of CPEB in each sample.   
The immunoprecipitation procedure resulted in much clearer results.  The 
western blot of samples following immunoprecipitation procedure shows that CPEB 
levels are increased in both high- and low-anxiety samples compared to control 
samples (Figure 3.10), which was confirmed by analysis of the repeated CPEB 
immunoprecipitations using Adobe Photoshop CS (Figure 3.11).  One-way ANOVA 
revealed a significant difference between the groups.   
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Figure 3.9: Western Blot of Aurora A, CaMKII, CPEB and β
 actin in Control, High- and Low-Anxiety Brain Samples
 and PC12 cells. PC12 cells were used as a control.
 Arrows denote location of faint bands in Aurora A,
 CaMKII and CPEB western blots.  
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3.8 Protein expression of CaMKII and Aurora A Kinase in 
Control, High- and Low- anxiety brain tissue 
 
To catalyze polyadenylation and therefore effect translation, CPEB must be 
phosphorylated; otherwise it is a repressor of translation.  To understand if the 
increase in CPEB expression results in increased translation or repression, the 
phosphorylation state of CPEB needs to be established.  Unfortunately no antibody 
to phosphorylated CPEB is available commercially or from another research 
laboratory.  Therefore, in order to gain insight into the activity of CPEB in anxiety, 
the expression of a known upstream kinase, Aurora A kinase, and a downstream 
target, calcium/calmodulin-dependent protein kinase II (CaMKII) was examined.  
Like the CPEB western results, Aurora A kinase and CaMKII also produced very 
faint bands (Figure 3.9). The CaMKII results were slightly more intense for the 
brain samples and the PC12 control band was strong.  Thus, as in CPEB, an 
immunoprecipitation was performed, which resulted in much clearer results (Figure 
3.10).   
The expression of CaMKII is increased in high-anxiety only.  Analysis of 
the blots shows that CaMKII is expressed in similar levels in control and low-
anxiety (Figure 3.12).  One-way ANOVA analysis showed significant difference 
between groups. This suggests increased translation of CaMKII and therefore an 
increase in CPEB activity in high-anxiety.  
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The results for the immunoprecipitation of Aurora A Kinase were more 
difficult to interpret.  The western blot of the initial immunoprecipitation showed a 
slight increase in expression in control and high-anxiety over low-anxiety (shown in 
Figure 3.10).  Each repetition of the immunoprecipitation and western blot resulted 
in more uniform bands.  These experiments were always done in parallel with 
CaMKII, which showed very little variability while the uniformity of Aurora A 
blots grew with each repetition.  Thus, the overall expression levels of Aurora A 
among control and high- and low-anxiety groups are not statistically significant 
(Figure 3.13). 
 
 
Figure 3.10: Western Blot of Immunoprecipitation of
 Control, High- and Low-Anxiety Brain Samples
 against Aurora A, CaMKII, CPEB  
 
 68
Figure 3.11: Relative Band intensities of Western Blot of CPEB in control, high- and low-
anxiety samples.  *p<0.05 n=3 
Figure 3.12 Relative Band intensities of Western Blot of CaMKII in Control, High and Low 
anxiety samples.  *p<0.05 n=3 
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Figure 3.13 Relative Band intensities of Western Blot of Aurora A Kinase in control, high- 
and low-anxiety samples. *p<0.05 n=3 
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4 Discussion 
 
Anxiety disorders are one of the most common psychiatric disorders.  Yet 
little is known about the molecular mechanisms behind the genesis or maintenance 
of these disorders.  An understanding of these mechanisms is the key to developing 
better diagnostic techniques and treatments.  The increased availability of gene 
sequence information and new molecular techniques have made it easier than ever 
to study these complex molecular workings. 
 
4.1 Anxiety Model 
 
Studying a complex psychiatric disorder in a rodent is inherently difficult, 
yet it is often the only method available to gain insight into the molecular 
mechanisms underlying these disorders.  The results of this project are not only 
influenced but possibly limited by two decisions made at the beginning.  First is the 
choice of behavior test.  There are many different behavior tests for anxiety in 
rodents and each one has draw backs.  The conditioned tests, while more amenable 
to experimental manipulation (Flint, 2003), measure a conditioned or learned 
response (Hitzemann, 2000).  As the anxious response measured by the test is 
learned it does not seem to be the appropriate choice to study different levels of 
inherent anxiety.  The unconditioned tests on the other hand do not involve training 
and so are believed to measure un-learned or inherent fear.  While there are 
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numerous unconditioned tests for anxiety that may have been equally appropriate 
the EPM was chosen for this project as it is extensively used and highly validated in 
anxiety research (Gordon and Hen, 2004; Hogg, 1996; Pellow et al., 1985; Rodgers 
and Dalvi, 1997).   
Like all other behavior tests, the EPM is extremely sensitive to outside 
factors.  Housing conditions, lighting, test duration and prior handling have all been 
shown to affect the test results (Rodgers and Dalvi, 1997).  To reduce the impact of 
these factors great care was taken to ensure that all the rats were treated identically 
and strict testing standards were maintained.  Even with the dedicated attention to 
detail our testing procedure produced an interesting effect; the open arm times were 
higher than expected for the EPM.  This has been attributed to the presence of the 
observers in the room which may have decreased the anxiogenic properties of the 
open arms.  From these results it is highly recommended that observation of the 
maze be carried out by a video capture system.   
Validation of the rats selected for their high- or low-anxiety by other 
behavior tests may have been beneficial, although Ho et al. (2002) has shown that 
the behavior of Wistar rats on the EPM has been shown to reliably predict their 
behavior in other anxiety tests.  Also, different anxiety tests may measure different 
aspects of anxiety (Hitzemann, 2000) so additional testing using a different test may 
have confounded the results instead of strengthening them.  
The second design decision that has a large impact on this study is the brain 
areas selected for investigation.  Anxiety is controlled by many brain areas, 
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including various brain stem, limbic and cortical regions.  While each brain area is 
an important contributor to anxiety it was not possible to study them all.  As a result 
we chose to investigate three brain areas associated with the limbic system, the 
amygdala, the hippocampus and the nucleus accumbens.  The limbic system is 
believed to play a central role in anxiety (Sandford et al., 2000).  The amygdala was 
chosen due to its role in processing fearful stimuli and its extensive interconnections 
controlling locomotor, neuroendocrine, autonomic, and respiratory responses 
(Gordon and Hen, 2004; Lang et al., 2000; Sandford et al., 2000).  The 
hippocampus was of interest due to its role in learning and memory, especially the 
evidence that a hypersensitive hippocampus may be biased towards negative 
associations (Gray and McNaughton, 2000).  Lastly, the nucleus accumbens was 
chosen due to its central position between many of the brain regions involved in the 
development of anxiety disorders and its involvement in aversive reinforcement 
(Sturm et al., 2003).  
After isolation of the three selected brain regions they were pooled together 
before the isolation of the mRNA. This was to ensure there was enough mRNA for 
making the cDNA samples and for the subsequent suppression subtractive 
hybridization experiment.  While this ensured a high mRNA concentration it may 
have influenced the final result.  It is possible that certain genes were regionally 
expressed in one brain structure and not in the other two.  Not only could we not 
detect regional changes but this may also have masked genes only upregulated in 
 73
one brain region.  Future investigations using isolated brain regions should be 
investigated and could possible identify such genes.   
 
4.2 Application of Molecular Techniques in the Study of 
Anxiety 
 
4.2.1 cDNA Microarray 
 
cDNA microarray is one molecular technique that has recently become quite 
popular.  A single hybridization step occurs between the test sample and a group of 
labeled, known cDNAs placed on a substrate.  This method allows a wide array of 
gene expression levels to be examined in a relatively short period of time. A recent 
study employed cDNA microarray to examine genes over-expressed in the rat 
model of anxiety (Wang et al., 2003). Unfortunately there are drawbacks to cDNA 
microarray that limit its usefulness in this investigation.   cDNA microarray cannot 
be used as a tool to examine unknown sequences as known sequences are applied to 
the array substrate for hybridization (Strakhova and Skolnick, 2001).  The cDNA 
can only be probed by one test population.  Using this approach, we would require 
two arrays; one for high-anxiety and one for low-anxiety.  With the requirement of 
specialized scanners and software for their analysis this makes the cost quite 
prohibitive (Strakhova and Skolnick, 2001).  Also, even with the proper equipment, 
analysis of gene expression using cDNA microarray is plagued by external 
inconsistencies such as pixel intensity and spot shape (Wang et al., 2003). 
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4.2.2 Suppression Subtractive Hybridization    
  
An attractive alternative to the popular cDNA microarray is suppression 
subtractive hybridization.  This technique uses two complete populations of cDNA 
for its hybridization steps, as opposed to cDNA microarray’s one population.  Also 
while cDNA identifies upregulated genes in one population, suppression subtractive 
hybridization allows the identification of up- and down-regulated genes by using 
two populations as both tester and driver in parallel (Strakhova and Skolnick, 2001).  
Suppression subtractive hybridization is also more sensitive to rare transcripts than 
cDNA microarray due to its PCR based suppression step (Strakhova and Skolnick, 
2001).  Thus, while more labor intensive, suppression subtractive hybridization 
appears to be the more appropriate choice in this quest to gain new insight into the 
molecular mechanisms of anxiety.  
A recent study examined anxiety-related genes in the rat amygdala using 
suppression subtractive hybridization (Koks et al., 2004). It has been shown that 
anxiety disorders involve multiple brain areas (such as the amygdala, hippocampus 
and nucleus accumbens) working together to process anxiogenic stimuli and 
generate the appropriate response (Bannerman et al., 2004; Graeff et al., 1993, 
Lesch, 2001; Pezze and Feldom, 2004; Swift and Swift, 2005). Therefore, our 
present study on anxiety-related genes in the amygdala, hippocampus and nucleus 
accumbens would provide a better understanding of mechanism underlying anxiety 
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development. As previous studies have induced an anxious state, either using a cat 
or its odor, before the application of cDNA microarray (Wang et al., 2003) or 
suppression subtractive hybridization (Koks et al., 2004), genes identified in these 
studies may include those related to stress itself but not anxiety. To exclude this 
possibility and to identify the genes that confer a possible predisposition to anxiety, 
we chose to identify rats with inherently high or low levels of anxiety prior to 
suppression subtractive hybridization. 
 
4.3 Anxiety-related Genes 
 
By using suppression subtractive hybridization in this project numerous 
genes were found upregulated in high- and low-anxiety. Some genes upregulated in 
high-anxiety have also been identified in another study of gene expression using 
suppression subtractive hybridization.  These include tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase, CaMKII, calmodulin and gelsolin 
(Koks et al., 2004).  Many other genes identified in this study have never been 
reported to be associated with anxiety before.  
 This extensive list of candidate genes provides a starting point for future 
studies of the molecular mechanisms of anxiety and may prove to be exciting targets 
for future pharmacotherapies.  For example, of the 102 low-anxiety genes, the 
wolframin gene (accession number AJ011971.1|MMU011971) appears to be of 
great interest (Table 3.2).  The wolframin gene is highly expressed in the amygdala 
and the CA1 region of the hippocampus.  Carriers of a single wolframin mutation 
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have been shown to have a predisposition to psychiatric illness (Swift and Swift, 
2005).  The wolframin gene was found to be upregulated in anxiety in the Koks 
study using suppression subtractive hybridization (Koks et al., 2004).  Perhaps the 
difference in expression levels may be accounted for by our inclusion of the nucleus 
accumbens and the hippocampus in our samples.   
Of 62 genes upregulated in the high-anxiety group (Table 3.2), several genes 
may play a role in anxiety.  Activating transcription factor 4 (ATF4, accession 
number BC061546.1) is homologous to the CREB-2 protein.  It has been shown that 
ATF4 hinders the transfer of short-term synaptic potential and memory storage to 
their long-term forms (Chen et al., 2003). Neuronal protein 25 (NP25, accession 
number M84725.1|RATNP25GN) is highly expressed in the hippocampus, frontal 
cortex, cerebellum and midbrain (Ren et al., 1994).  Immobilization stress has been 
shown to increase the activity of NP25 in the frontal cortex and hippocampus, 
suggesting a role in stress-mediated mental disorders (Morinobu et al., 2003).  The 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 
(accession number NM_013053.1) is part of the 14-3-3 protein family that is found 
to be highly expressed in the large projection neurons of the hippocampus, 
cerebellum and spinal cord (Malaspina et al., 2000) and was also found to be 
upregulated in the Koks study (Koks et al., 2004).  The 14-3-3 proteins play 
essential roles in key signaling pathways of apoptosis and cell proliferation 
(Malaspina et al., 2000). Synaptotagmin I (accession number NM_001033680) is a 
regulator of calcium-dependent exocytosis and endocytosis (Nicholson-Tomishima 
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and Ryan, 2004).  Synaptotagmin IV, a protein of the same family, has been shown 
to be involved in anxiety (Ferguson, et al., 2004).  The gene encoding the prion 
protein (accession number NM_012631.2) was found to be upregulated in high-
anxiety rats.  Further investigation into the literature revealed the prion protein may 
play a role in excitatory neurotransmission (Carleton et al., 2001) and a role 
modulating anxiety (Nico et al., 2005).   
Any of the genes identified in the suppression subtractive hybridization 
study would have made for fascinating research subjects but we decided to follow a 
lead brought to our attention by the prion protein literature.  CPEB was first brought 
to our attention as a prion-like protein.  Further investigation into the literature 
showed CPEB to be involved in experience-dependent protein translation and as a 
result could be a key component of learning and memory (Huang et al,. 2002; Wu et 
al., 1998).  It was also revealed that CPEB-dependent polyadenylation (and 
subsequent translation) of specific mRNAs was dependent on activation of the 
NMDA receptor.  As excessive neuronal hyper-excitability is anxiogenic (Lydiard, 
2003) and CPEB activity is regulated by the NMDA receptor we decided to 
investigate the possibility that CPEB is overactive in anxiety. While CPEB was not 
directly identified by the suppression subtractive hybridization it would not have 
been brought to our attention had it not been for the identification of the prion 
protein in the list for high-anxiety.  
The results of this project have shown CPEB to be present in the adult rat 
hippocampus in both mRNA and protein form by PCR and western blot analysis, 
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respectively. To understand the role of CPEB in anxiety, its normal role in the brain 
should be discussed.  Results from the work done by other research groups have 
highlighted a key role for CPEB in the long-term maintenance of synaptic plasticity.  
CPEB is located in the center of a pathway critical for long-term potentiation (LTP).  
In normal function it perhaps plays a significant part in the mechanism of long-term 
memory formation.   
 
4.4 Synaptic Plasticity 
 
The neural mechanism of memory has been an intriguing subject for many 
years.  Synaptic plasticity is thought to be a key component of the formation of 
memories (Si et al., 2003; Wells et al., 2001).  It can be defined as a modulation of 
synaptic strength and is based on the history of that synapse (Huang et al., 2002; Si 
et al., 2003; Wells et al., 2001).  The long-term form of synaptic plasticity, which is 
believed to underlie the long-term maintenance of memory, has been shown to 
require new protein synthesis and the formation of new connections. 
 A large collection of evidence has shown that the new protein synthesis 
required for synaptic plasticity occurs within the activated synapse itself.   The 
dendritic compartments of neurons contain all the necessary cellular machinery to 
translate mRNAs locally (Huang et al., 2002; Richter, 1999).  Electron microscopy 
has shown polyribosomes associating with postsynaptic structures.  Hippocampal 
dendrites have been shown to contain RNA molecules and protein components 
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required for protein synthesis (Huang, 1999).   More conclusive studies have shown 
protein synthesis to occur in isolated dendritic or synaptic compartments (Huang et 
al., 2002).  Long-lasting phase of LTP, which requires new protein synthesis, can be 
established in dendritic layers alone (Huang et al., 2002). 
 Only a select group of mRNAs are translated at the synapse.  More 
specifically, dendrites contain specific mRNAs that may be involved in synaptic 
plasticity.  High levels of mRNAs, including those for microtubule-associated 
protein MAP2, α subunit of the calcium/calmodulin-dependent protein kinase II 
(CaMKII) and an immediate early gene, Arc, have been found to be co-localized 
with the protein synthesis machinery in dendrites (Huang, 1999).   
The translation of these specific mRNAs does not occur in all the dendrites 
of a given neuron.   Synaptic activity has been shown to trigger the translation of 
these mRNAs only at specific synapses within the same neuron.  Arc mRNA has 
been shown to be concentrated only in the active dendrites of a single neuron.   
Strong stimulation of hippocampal and cortical neurons resulted in the increase of 
the Arc protein within their dendrites (Huang, 1999).  CaMKII has the same pattern 
of expression.  Strong stimulation of hippocampal slices resulted in increased 
protein expression of CaMKII specifically in the dendrites (Huang, 1999).   
CPEB may be the regulator of the protein synthesis required for synaptic 
plasticity.  Research into the translational control of Xenopus oocytes has shown 
CPEB can keep mRNAs translationally dormant until it becomes phosphorylated.  
The phosphorylation event triggers polyadenylation and translation of the bound 
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mRNA.  Within dendrites the same mechanism exists.  CPEB has been shown to 
hold specific mRNAs dormant in the dendrite until the dendrite becomes activated.  
After stimulation CPEB becomes phosphorylated and triggers the translation of the 
dormant mRNAs, including CaMKII (Huang et al., 2002; Wu et al., 1998).  
The signal that triggers CPEB phosphorylation is the N-methyl-D-aspartate 
(NMDA) receptor. Huang et al., (2002) found that NMDA receptor signaling 
triggered Aurora A kinase to phosphorylate CPEB and therefore catalyze the 
polyadenylation of specific mRNAs at the activated synapse. NMDA receptor is 
also known to mediate mechanisms required for memory consolidation (Izquierdo 
and Medina, 1997).   
CPEB may be a key regulator of synaptic plasticity, a key component of 
learning and memory. CPEB may play a role in the development of changes in 
neural plasticity that may create a “long-term behavioral sensitization” which can 
lead to anxiety disorders (Rainnie et al., 2004). How these long-term changes in 
neural plasticity lead to anxiety is unknown. Glutamatergic neurotransmission and 
the NMDA receptor have already been shown to be key components.  CPEB 
regulation of protein synthesis within specific synapses could be a major part of this 
process.  
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4.5 NMDA Receptor in Anxiety Disorders 
 
  
The involvement of the NMDA receptor in anxiety is well documented.  
Excessive neuronal hyper-excitability is believed to underlie the development of 
pathological anxiety (Lydiard, 2003) possibly in reaction to stress.  Stress can 
induce alterations in neural plasticity in a glutamatergic dependent manner (Du et 
al., 2004).  Stress exposure can also increase glutamate levels and NMDA receptor 
expression in the hippocampus (Boyce-Rustay and Holmes, 2006; Du et al., 2004).   
The NMDA receptor is believed to mediate mood and emotion-related behaviors as 
it is highly expressed in cortical and limbic regions (Bergink et al., 2004; Boyce-
Rustay and Holmes, 2006).   
Manipulation of the NMDA receptor has shown it to be a major player in 
anxiety.  The application of both competitive and non-competitive NMDA receptor 
antagonists have been shown to be anxiolytic in many rodent behavioral tests, 
including the EPM (Boyce-Rustay and Holmes, 2006).  NMDA receptor knockout 
mice show lowered anxiety-related behaviors than their wild type counterparts 
(Boyce-Rustay and Holmes, 2006).  The NMDA receptor has been shown to be 
critical in anxiety-related learning paradigms (Bergink et al., 2004).  In fear 
conditioning, for example, has been shown to be NMDA receptor dependent.  
Blocking the NMDA receptor with an antagonist blocks the acquisition of fear 
(Bergink et al., 2004).  The same mechanism has been shown to be involved in 
passive avoidance learning (Izquierdo and Medina, 1997).  NMDA dependent 
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neural plasticity is also a critical component of the acquisition of fear-potentiated 
startle (Adamec, 1997). 
 
4.6 Role of CPEB in Anxiety Disorders 
 
 
In this study CPEB has been shown to be upregulated in both high- and low-
anxiety rats over control.  These results are not in conflict with our data shown in 
Table 3.2, in which suppression subtractive hybridization revealed no significant 
difference in the expression levels of CPEB between high- and low-anxiety rats. 
Upregulation of CPEB in both high- and low-anxiety rats does not reveal any 
insight into its contribution to anxiety at first glance.  However, once these changes 
are viewed within the context of a pathway an interesting hypothesis emerges.  First, 
let us look at CPEB in high-anxiety.  As previously mentioned, the NMDA receptor 
plays a critical role in anxiety disorders because glutamatergic hyper-excitability is 
thought to underlie these disorders.  CPEB is known to lie downstream of the 
NMDA receptor and its phosphorylation is dependent upon NMDA activity.  
 In a control situation NMDA receptor activation catalyzes the 
polyadenylation of specific mRNAs through CPEB.  This leads to the long-term 
maintenance of synaptic plasticity.  In a high-anxiety state, CPEB is over-expressed.  
As a result, activation of the NMDA receptor may produce a much larger increase in 
protein synthesis through the increased presence of CPEB.  The stronger response 
could possibly create a much more sensitive synapse. 
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In low-anxiety state, there is also an increase in CPEB.  In this case, the 
result could be quite opposite.  Research has shown that blocking the NMDA 
receptor prevents lasting increases in anxiety behavior (Adamec, 1998).  It can be 
hypothesized that the NMDA receptor is less active in low-anxiety, either by its own 
downregulation or lower glutamatergic neurotransmission.  In either case less 
NMDA signaling would mean less CPEB would be phosphorylated.  
Unphosphorylated CPEB has been shown to act as a repressor.  When bound to 
specific mRNAs, unphosphorylated CPEB keeps mRNAs dormant by preventing 
the 40s subunit of the ribosome from interacting with and translating the mRNA.  In 
this case an excess of CPEB in a synapse would mean a smaller proportion of 
mRNAs would be translated after NMDA activation.  This could be protective 
against anxiety by creating stricter limitations on synaptic plasticity.  
Our working hypotheses described above are, at least partially, confirmed by 
our further findings in this study about CaMKII.  We have shown that high-anxiety 
rats, but not low-anxiety rats, showed significantly increased expression levels of 
CaMKII, the downstream effector of CPEB. CaMKII was found to be upregulated 
in both the suppression subtractive hybridization (Table 3.2, number 47 in high- 
anxiety gene list) and immunoprecipitation experiments (Figures 3.10, 3.12), 
suggesting the reliability of these data. Another recent study by Koks et al., using 
suppression subtractive hybridization, also showed similar results in the rat 
amygdala after cat odor-induced anxiety (Koks et al., 2004). All these results 
strongly suggest an important involvement of CaMKII in inducing anxiety. 
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Like its upstream effectors NMDA receptor and CPEB, CaMKII is a known 
mediator of synaptic plasticity.  CaMKII is believed to play a role as a “memory 
switch” as it can orchestrate the long-term strengthening of a synapse through many 
signaling cascades (Du et al., 2004).  CaMKII has been shown to be critical for the 
long-term maintenance of the LTP (Du et al., 2004).  Like the NMDA receptors 
(Boyce-Rustay and Holmes, 2006), CaMKII has also been shown to be increased 
after stress exposure (Suenaga et al., 2004).  Thus, it appears as though increased 
activity of the NMDA-CPEB-CaMKII pathway may prove to be important in the 
development and/or maintenance of anxiety disorders 
  
4.7 CPEB in Man  
 
 
CPEB has been found to be present in many organisms from invertebrates, 
like Aplysia californica, to frogs, zebrafish, mice and rats.  In 2001, the human 
CPEB was cloned.  It was found to be in high concentrations in adult ovary and 
brain (Welk et al., 2001).  The human CPEB bears potential to function like the 
CPEB found in adult rodents.  It is able to bind RNA in a sequence-specific manner 
just like Xenopus and Mus CPEBs (Welk et al., 2001).  Thus it is likely that the 
findings of CPEB activity in rodents may hold for humans also. 
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4.8 Future Directions  
 
This project has provided two sets of results that hold potential to uncover 
important and novel molecular mechanisms involved in anxiety. Firstly, the gene 
lists derived from the suppression subtractive hybridization hold great promise.  
While there are many genes that have no known link to anxiety disorders some are 
beginning to accumulate promising evidence such as CaMKII and the cellular prion 
protein.  Many of the identified genes may be investigated in detail from molecular 
work back to behavior using in vivo studies. Any one may result in new insight into 
the molecular mechanisms of anxiety.  
Secondly, the CPEB results presented here are preliminary.  Due to the lack 
of an antibody specific to phosphorylated CPEB we were only able to infer that 
CPEB is overactive in high-anxiety.  Development of a phosphorylated antibody 
will allow confirmation of the phosphorylation state of the over-expressed CPEB in 
high-anxiety.  Identification of other CPE containing targets of CPEB would be an 
asset.  Finally the role of CPEB in synaptic plasticity, learning and memory and its 
relation to anxiety should be investigated possibly through the use of a conditioned-
fear paradigm.       
Further investigation into either the gene list presented in this project or 
CPEB may lead to a better understanding of the molecular mechanisms underlying 
both “normal” and “pathological” anxiety.  Ideally this work will lead to more 
effective treatments for such a prevalent and disabling disorder. 
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